Document:

<PAGE>

                                                                     Exhibit 4.1

                     STOCKHOLDER PROTECTION RIGHTS AGREEMENT

                                   DATED AS OF

                                  MAY 22, 2001

                                     BETWEEN

                      FIRST FEDERAL FINANCIAL BANCORP, INC.

                                       AND

                         REGISTRAR AND TRANSFER COMPANY

                                 AS RIGHTS AGENT

<PAGE>

                     STOCKHOLDER PROTECTION RIGHTS AGREEMENT

                                TABLE OF CONTENTS

                                    ARTICLE I

                               CERTAIN DEFINITIONS

<TABLE>
<CAPTION>
                                                                                                 PAGE
                                                                                                 ----
<S>     <C>                                                                                       <C>
Section 1.1 Certain Definitions....................................................................1

                                   ARTICLE II
                                   THE RIGHTS

Section 2.1  Summary of Rights.....................................................................5
Section 2.2  Legend of Common Stock Certificates...................................................6
Section 2.3  Exercise of Rights; Separation of Rights..............................................6
Section 2.4  Adjustments to Exercise Price; Number of Rights.......................................8
Section 2.5  Date on which Exercise is Effective...................................................9
Section 2.6  Execution, Authentication, Delivery and Dating of Rights Certificates.................9
Section 2.7  Registration, Registration of Transfer and Exchange ..................................9
Section 2.8  Mutilated, Destroyed, Lost and Stolen Rights Certificates............................10
Section 2.9  Persons Deem Owners..................................................................11
Section 2.10 Delivery and Cancellation of Certificates............................................11
Section 2.11 Agreement of Rights Holders..........................................................11

                                   ARTICLE III
         ADJUSTMENTS OF THE RIGHTS IN THE EVENT OF CERTAIN TRANSACTIONS

Section 3.1  Flip-in..............................................................................12
Section 3.2  Flip-over............................................................................13

                                   ARTICLE IV
                                THE RIGHTS AGENT

Section 4.1  General..............................................................................14
Section 4.2  Merger or Consolidation or Change of Name of Rights Agent............................14
Section 4.3  Duties of Rights Agent...............................................................15
Section 4.4  Change of Rights Agent...............................................................17

                                    ARTICLE V
                                  MISCELLANEOUS

Section 5.1  Redemption...........................................................................17
Section 5.2  Expiration...........................................................................18
Section 5.3  Issuance of New Rights Certificates..................................................18

                                       i
<PAGE>

Section 5.4  Supplements and Amendments...........................................................18
Section 5.5  Fractional Shares....................................................................18
Section 5.6  Rights of Action.....................................................................19
Section 5.7  Holder of Rights Not Deemed a Stockholder............................................19
Section 5.8  Notice of Proposed Actions...........................................................19
Section 5.9  Notices..............................................................................19
Section 5.10 Suspension of Exercisability.........................................................20
Section 5.11 Cost of Enforcement..................................................................20
Section 5.12 Successors...........................................................................20
Section 5.13 Benefits of this Agreement...........................................................20
Section 5.14 Determination and Actions by the Board of Directors..................................21
Section 5.15 Descriptive Headings.................................................................21
Section 5.16 Governing Law........................................................................21
Section 5.17 Counterparts.........................................................................21
Section 5.18 Severability.........................................................................21

                                    EXHIBITS

Exhibit A    Form of Rights Certificate (Together with Form of Election to Exercise)

Exhibit B    Form of Certificate of Designations, Preferences and Rights of Series A Junior
             Participating Preferred Stock of First Federal Financial Bancorp, Inc.

Exhibit C    Form of Summary of Rights to Purchase Preferred Stock or Common Stock
</TABLE>

                                       ii
<PAGE>

                     STOCKHOLDER PROTECTION RIGHTS AGREEMENT

      STOCKHOLDER PROTECTION RIGHTS AGREEMENT (as amended from time to time,
this "Agreement"), dated as of May 22, 2001, between First Federal Financial
Bancorp, Inc., a Delaware corporation (the "Company"), and Registrar and
Transfer Company, Cranford, New Jersey, as Rights Agent (the "Rights Agent,"
which term shall include any successor Rights Agent hereunder).

                                   WITNESSETH:

      WHEREAS, the Board of Directors of the Company has (a) authorized and
declared a dividend of one right ("Right") in respect of each share of Common
Stock (as hereinafter defined) held of record as of the close of business on May
23, 2001 (the "Record Time") and (b) as provided in Section 2.4, authorized the
issuance of one Right in respect of each share of Common Stock issued after the
Record Time and prior to the Separation Time (as hereinafter defined) and, to
the extent provided in Section 5.3, each share of Common Stock issued after the
Separation Time;

      WHEREAS, subject to Sections 3.1, 3.2, 5.1 and 5.10, each Right entitles
the holder thereof, after the Separation Time, to purchase securities of the
Company (or, in certain cases, of certain other entities) pursuant to the terms
and subject to the conditions set forth herein; and

      WHEREAS, the Company desires to appoint the Rights Agent to act on behalf
of the Company, and the Rights Agent is willing so to act, in connection with
the issuance, transfer, exchange and replacement of Rights Certificates (as
hereinafter defined), the exercise of Rights and other matters referred to
herein;

      NOW THEREFORE, in consideration of the premises and the respective
agreements set forth herein, the parties hereby agree as follows:

                                    ARTICLE I

                               CERTAIN DEFINITIONS

      1.1 CERTAIN DEFINITIONS. For purposes of this Agreement, the following
terms have the meanings indicated:

      "Acquiring Person" shall mean any Person who is a Beneficial Owner of 10%
or more of the outstanding shares of Common Stock; PROVIDED, however, that the
term "Acquiring Person" shall not include any Person (i) who acquired Beneficial
Ownership of 10% or more of the outstanding shares of Common Stock pursuant to
an offer for one hundred percent (100%) of the outstanding shares of Common
Stock at a price and on terms determined by at least a majority of the Board of
Directors of the Company to be both adequate and otherwise in the best interests
of the Company and its stockholders (other than the Person or an Affiliate or
Associate thereof on whose behalf the offer is being made) (a "Permitted
Offer"), (ii) who is the Beneficial Owner of 10% or more of the outstanding
shares of Common Stock but who acquired Beneficial Ownership of shares of Common
Stock without any plan or intention to seek or affect control of

<PAGE>

the Company, if such Person promptly enters into an irrevocable commitment
promptly to divest, and thereafter promptly divests (without exercising or
retaining any power, including voting, with respect to such shares), sufficient
shares of Common Stock (or securities convertible into, exchangeable into or
exercisable for Common Stock) so that such Person ceases to be the Beneficial
Owner of 10% or more of the outstanding shares of Common Stock or (iii) who
Beneficially Owns shares of Common Stock consisting solely of one or more of (A)
shares of Common Stock Beneficially Owned pursuant to the grant or exercise of
an option granted to such Person by the Company in connection with an agreement
to merge with, or acquire, the Company entered into prior to a Flip-in Date, (B)
shares of Common Stock (or securities convertible into, exchangeable into or
exercisable for Common Stock), Beneficially Owned by such Person or its
Affiliates or Associates at the time of grant of such option, (C) shares of
Common Stock (or securities convertible into, exchangeable into or exercisable
for Common Stock) acquired by Affiliates or Associates of such Person after the
time of such grant which, in the aggregate, amount to less than 1% of the
outstanding shares of Common Stock, and (D) shares of Common Stock (or
securities convertible into, exchangeable into or exercisable for Common Stock)
which are held by such Person in trust accounts, managed accounts and the like
or otherwise held in a fiduciary capacity, that are beneficially owned by third
persons who are not Affiliates or Associates of such Person or acting together
with such Person to hold such shares, or which are held by such Person in
respect of a debt previously contracted. In addition, the Company, any wholly
owned Subsidiary of the Company and any employee stock ownership or other
employee benefit plan of the Company or a wholly owned Subsidiary of the Company
shall not be an Acquiring Person.

      "Affiliate" and "Associate" shall have the respective meanings ascribed to
such terms in Rule 12b-2 under the Securities Exchange Act of 1934, as amended
(the "Securities Exchange Act"), as such Rule is in effect on the date of this
Agreement.

      A Person shall be deemed the "Beneficial Owner," and to have "Beneficial
Ownership" of, and to "Beneficially Own," any securities as to which such Person
or any of such Person's Affiliates or Associates is or may be deemed to be the
beneficial owner of pursuant Rules 13d-3 and 13d-5 under the Securities Exchange
Act, as such Rules are in effect on the date of this Agreement (irrespective of
whether the Company is subject to the Securities Exchange Act), as well as any
securities as to which such Person or any of such Person's Affiliates or
Associates has the right to become Beneficial Owner (whether such right is
exercisable immediately or only after the passage of time or the occurrence of
conditions) pursuant to any agreement, arrangement or understanding, or upon the
exercise of conversion rights, exchange rights, rights (other than the Rights),
warrants or options, or otherwise; PROVIDED, HOWEVER, that a Person shall not be
deemed the "Beneficial Owner," or to have "Beneficial Ownership" of, or to
"Beneficially Own," any security (i) solely because such security has been
tendered pursuant to a tender or exchange offer made by such Person or any of
such Person's Affiliates or Associates until such tendered security is accepted
for payment or exchange or (ii) solely because such Person or any of such
Person's Affiliates or Associates has or shares the power to vote or direct the
voting of such security pursuant to a revocable proxy given in response to a
public proxy or consent solicitation made to more than ten holders of shares of
a class of stock of the Company registered under Section 12 of the Securities
Exchange Act and pursuant to, and in accordance with, the applicable rules and
regulations under the Securities Exchange Act, except if such power (or the

                                       2
<PAGE>

arrangements relating thereto) is then reportable under Item 6 of Schedule 13D
under the Securities Exchange Act (or any similar provision of a comparable or
successor report). Notwithstanding the foregoing, no officer or director of the
Company shall be deemed to Beneficially Own any securities of any other Person
by virtue of any actions such officer or director takes in such capacity. For
purposes of this Agreement, in determining the percentage of the outstanding
shares of Common Stock with respect to which a Person is the Beneficial Owner,
all shares as to which such Person is deemed the Beneficial Owner shall be
deemed outstanding.

      Business Day" shall mean any day other than a Saturday, Sunday or a day on
which banking institutions in Ohio are generally authorized or obligated by law
or executive order to close.

      "Close of business" on any given date shall mean 5:00 p.m., Eastern Time,
on such date (or, if such date is not a Business Day, 5:00 p.m., Eastern Time,
on the next succeeding Business Day).

      "Common Stock" shall mean the shares of Common Stock, par value $.0l per
share, of the Company.

      "Exchange Time" shall mean the time at which the right to exercise the
Rights shall terminate pursuant to Section 3.1(c) hereof.

      "Exercise Price" shall mean, as of any date, the price at which a holder
may purchase the securities issuable upon exercise of one whole Right. Until
adjustment thereof in accordance with the terms hereof, the Exercise Price shall
equal $40.00 per Right.

      "Expiration Time" shall mean the earlier of (i) the Exchange Time, (ii)
the Redemption Time, (iii) May 23, 2011 and (iv) upon the merger of the Company
into another corporation pursuant to an agreement entered into prior to a
Flip-in Date.

      "Flip-in Date" shall mean the tenth business day after any Stock
Acquisition Date or such earlier or later date as the Board of Directors of the
Company may from time to time fix by resolution adopted prior to the Flip-in
Date that would otherwise have occurred.

      "Flip-over Entity," for purposes of Section 3.2, shall mean (i) in the
case of a Flip-over Transaction or Event described in clause (i) of the
definition thereof, the Person issuing any securities into which shares of
Common Stock are being converted or exchanged and, if no such securities are
being issued, the other party to such Flip-over Transaction or Event and (ii) in
the case of a Flip-over Transaction or Event referred to in clause (ii) of the
definition thereof, the Person receiving the greatest portion of the assets or
earning power being transferred in such Flip-over Transaction or Event, provided
in all cases if such Person is a subsidiary of a corporation, the parent
corporation shall be the Flip-over Entity.

      "Flip-over Stock" shall mean the capital stock (or similar equity
interest) with the greatest voting power in respect of the election of directors
(or other persons similarly responsible for direction of the business and
affairs) of the Flip-over Entity.

                                       3
<PAGE>

      "Flip-over Transaction or Event" shall mean a transaction or series of
transactions after a Flip-in Date in which, directly or indirectly, (i) the
Company shall consolidate or merge or participate in a share exchange with any
other Person if, at the time of the consolidation, merger or share exchange or
at the time the Company enters into any agreement with respect to any such
consolidation, merger or share exchange, the Acquiring Person Controls the Board
of Directors of the Company and either (A) any term of or arrangement concerning
the treatment of shares of capital stock in such consolidation, merger or share
exchange relating to the Acquiring Person is not identical to the terms and
arrangements relating to other holders of the Common Stock or (B) the Person
with whom the transaction or series of transactions occurs is the Acquiring
Person or an Affiliate or Associate of the Acquiring Person or (ii) the Company
shall sell or otherwise transfer (or one or more of its Subsidiaries shall sell
or otherwise transfer) assets (A) aggregating more than 50% of the assets
(measured by either book value or fair market value) or (B) generating more than
50% of the operating income or cash flow, of the Company and its Subsidiaries
(taken as a whole) to any Person (other than the Company or one or more of its
wholly owned Subsidiaries) or to two or more such Persons which are Affiliates
or Associates or otherwise acting in concert, if, at the time of the entry by
the Company (or any such Subsidiary) into an agreement with respect to such sale
or transfer of assets, the Acquiring Person Controls the Board of Directors of
the Company. An Acquiring Person shall be deemed to Control the Company's Board
of Directors when, following a Flip-in Date, the persons who were directors of
the Company before the Flip-in Date shall cease to constitute a majority of the
Company's Board of Directors.

      "Market Price" per share of any securities on any date shall mean the
average of the daily closing prices per share of such securities (determined as
described below) on each of the 20 consecutive Trading Days through and
including the Trading Day immediately preceding such date; PROVIDED, HOWEVER,
that if an event of a type analogous to any of the events described in Section
2.4 hereof shall have caused the closing prices used to determine the Market
Price on any Trading Days during such period of 20 Trading Days not to be fully
comparable with the closing price on such date, each such closing price so used
shall be appropriately adjusted in order to make it fully comparable with the
closing price on such date. The closing price per share of any securities on any
date shall be the last reported sale price, regular way, or, in case no such
sale takes place or is quoted on such date, the average of the closing bid and
asked prices, regular way, for each share of such securities, in either case as
reported in the principal consolidated transaction reporting system with respect
to securities listed or admitted to trading on the New York Stock Exchange, Inc.
or, if the securities are not listed or admitted to trading on the New York
Stock Exchange, Inc., as reported in the principal consolidated transaction
reporting system with respect to securities listed on the principal national
securities exchange on which the securities are listed or admitted to trading
or, if the securities are not listed or admitted to trading on any national
securities exchange, as reported by the Nasdaq Stock Market or such other system
then in use, or, if on any such date the securities are not listed or admitted
to trading on any national securities exchange or quoted by any such
organization, the average of the closing bid and asked prices as furnished by a
professional market maker making a market in the securities selected by the
Board of Directors of the Company; PROVIDED, HOWEVER, that if on any such date
the securities are not listed or admitted to trading on a national securities
exchange or traded in the over-the counter market, the closing price per share
of such securities on such date shall mean the fair value per share of
securities on such date as determined in good faith by the

                                       4
<PAGE>

Board of Directors of the Company, after consultation with a nationally
recognized investment banking firm, and set forth in a certificate delivered to
the Rights Agent.

      "Person" shall mean any individual, firm, partnership, association, group
(as such term is used in Rule 13d-5 under the Securities Exchange Act, as such
Rule is in effect on the date of this Agreement), corporation or other entity.

      "Preferred Stock" shall mean the series of Series A Junior Participating
Preferred Stock, par value $.01 per share, of the Company created by the
Certificate of Designations, Preferences and Rights in substantially the form
set forth in Exhibit B hereto appropriately completed.

      "Redemption Price" shall mean an amount equal to one cent, $0.01.

      "Redemption Time" shall mean the time at which the right to exercise the
Rights shall terminate pursuant to Section 5.1 hereof.

      "Separation Time" shall mean the close of business on the earlier of(i)
the tenth business day (or such later date as the Board of Directors of the
Company may from time to time fix by resolution adopted prior to the Separation
Time that would otherwise have occurred) after the date on which any Person
commences a tender or exchange offer which, if consummated, would result in such
Person becoming an Acquiring Person and (ii) the Flip-in Date; PROVIDED, that if
the foregoing results in the Separation Time being prior to the Record Time, the
Separation Time shall be the Record Time and PROVIDED FURTHER, that if any
tender or exchange offer referred to in clause (i) of this paragraph is
canceled, terminated or otherwise withdrawn prior to the Separation Time without
the purchase of any shares of Common Stock pursuant thereto, such offer shall be
deemed, for purposes of this paragraph, never to have been made.

      "Stock Acquisition Date" shall mean the first date of public announcement
by the Company (by any means) that an Acquiring Person has become such.

      "Subsidiary" of any specified Person shall mean any corporation or other
entity of which a majority of the voting power of the equity securities or a
majority of the equity interest is Beneficially Owned, directly or indirectly,
by such Person.

      "Trading Day," when used with respect to any securities, shall mean a day
on which the New York Stock Exchange, Inc. is open for the transaction of
business or, if such securities are not listed or admitted to trading on the New
York Stock Exchange, Inc., a day on which the principal national securities
exchange on which such securities are listed or admitted to trading is open for
the transaction of business or, if such securities are not listed or admitted to
trading on any national securities exchange, a Business Day.

                                   ARTICLE II

                                   THE RIGHTS

      2.1 SUMMARY OF RIGHTS. As soon as practicable after the Record Time, the
Company will mail a letter, in substantially the form attached hereto as Exhibit
C, summarizing the terms

                                       5
<PAGE>

of the Rights to each holder of record of Common Stock as of the Record Time, at
such holder's address as shown by the records of the Company.

      2.2 LEGEND ON COMMON STOCK CERTIFICATES. Certificates for the Common Stock
issued after the Record Time but prior to the Separation Time shall evidence one
Right for each share of Common Stock represented thereby and shall have
impressed on, printed on, written on or otherwise affixed to them the following
legend:

            Until the Separation Time (as defined in the Rights Agreement
      referred to below), this certificate also evidences and entitles the
      holder hereof to certain Rights as set forth in a Stockholder Protection
      Rights Agreement, dated as of May 22, 2001 (as such may be amended from
      time to time, the "Rights Agreement"), between First Federal Financial
      Bancorp, Inc. (the "Company") and Registrar and Transfer Company, as
      Rights Agent, the terms of which are hereby incorporated herein by
      reference and a copy of which is on file at the principal executive
      offices of the Company. Under certain circumstances, as set forth in the
      Rights Agreement, such Rights may be redeemed, may become exercisable for
      securities or assets of the Company or of another entity, may be exchanged
      for shares of Common Stock or other securities or assets of the Company,
      may expire, may become void (if they are "Beneficially Owned" by an
      "Acquiring Person" or an Affiliate or Associate thereof, as such terms are
      defined in the Rights Agreement, or by any transferee of any of the
      foregoing) or may be evidenced by separate certificates and may no longer
      be evidenced by this certificate. The Company will mail or arrange for the
      mailing of a copy of the Rights Agreement to the holder of this
      certificate without charge promptly after the receipt of a written request
      therefor.

Certificates representing shares of Common Stock that are issued and outstanding
at the Record Time shall evidence one Right for each share of Common Stock
evidenced thereby notwithstanding the absence of the foregoing legend.

      2.3 EXERCISE OF RIGHTS; SEPARATION OF RIGHTS. (a) Subject to Sections 3.1,
5.1 and 5.10 and subject to adjustment as herein set forth, each Right will
entitle the holder thereof, after the Separation Time and prior to the
Expiration Time, to purchase, for the Exercise Price, one one-hundredth of a
share of Preferred Stock.

      (b) Until the Separation Time, (i) no Right may be exercised and (ii) each
Right will be evidenced by the certificate for the associated share of Common
Stock (together, in the case of certificates issued prior to the Record Time,
with the letter mailed to the record holder thereof pursuant to Section 2.1) and
will be transferable only together with, and will be transferred by a transfer
(whether with or without such letter) of, such associated share.

      (c) Subject to this Section 2.3 and to Sections 3.1, 5.1 and 5.10, after
the Separation Time and prior to the Expiration Time, the Rights (i) may be
exercised and (ii) may be transferred independent of shares of Common Stock.
Promptly following the Separation Time, the Rights Agent will mail to each
holder of record of Common Stock as of the Separation Time (other than any
Person whose Rights have become void pursuant to Section 3.1(b)), at such
holder's address as shown by the records of the Company (the Company hereby
agreeing to

                                       6
<PAGE>

furnish copies of such records to the Rights Agent for this purpose), (x) a
certificate (a "Rights Certificate") in substantially the form of Exhibit A
hereto appropriately completed, representing the number of Rights held by such
holder at the Separation Time and having such marks of identification or
designation and such legends, summaries or endorsements printed thereon as the
Company may deem appropriate and as are not inconsistent with the provisions of
this Agreement, or as may be required to comply with any law or with any rule or
regulation made pursuant thereto or with any rule or regulation of any national
securities exchange or quotation system on which the Rights may from time to
time be listed or traded, or to conform to usage, and (y) a disclosure statement
describing the Rights.

      (d) Subject to Sections 3.1, 5.1 and 5.10, Rights may be exercised on any
Business Day after the Separation Time and prior to the Expiration Time by
submitting to the Rights Agent the Rights Certificate evidencing such Rights
with an Election to Exercise (an "Election to Exercise") substantially in the
form attached to the Rights Certificate duly completed, accompanied by payment
in cash, or by certified or official bank check or money order payable to the
order of the Company, of a sum equal to the Exercise Price multiplied by the
number of Rights being exercised and a sum sufficient to cover any transfer tax
or charge which may be payable in respect of any transfer involved in the
transfer or delivery of Rights Certificates or the issuance or delivery of
certificates for shares or depositary receipts (or both) in a name other than
that of the holder of the Rights being exercised.

      (e) Upon receipt of a Rights Certificate, with an Election to Exercise
accompanied by payment as set forth in Section 2.3(d), and subject to Sections
3.1, 5.1 and 5.10, the Rights Agent will thereupon promptly (i) (A) requisition
from a transfer agent stock certificates evidencing such number of shares or
other securities to be purchased (the Company hereby irrevocably authorizing its
transfer agents to comply with all such requisitions) and (B) if the Company
elects pursuant to Section 5.5 not to issue certificates representing fractional
shares, requisition from the depositary selected by the Company depositary
receipts representing the fractional shares to be purchased or requisition from
the Company the amount of cash to be paid in lieu of fractional shares in
accordance with Section 5.5 and (ii) after receipt of such certificates,
depositary receipts and/or cash, deliver the same to or upon the order of the
registered holder of such Rights Certificate, registered (in the case of
certificates or depositary receipts) in such name or names as may be designated
by such holder.

      (f) In case the holder of any Rights shall exercise less than all the
Rights evidenced by such holder's Rights Certificate, a new Rights Certificate
evidencing the Rights remaining unexercised will be issued by the Rights Agent
to such holder or to such holder's duly authorized assigns.

      (g) The Company covenants and agrees that it will (i) take all such action
as may be necessary to ensure that all shares delivered upon exercise of Rights
shall, at the time of delivery of the certificates for such shares (subject to
payment of the Exercise Price), be duly and validly authorized, executed, issued
and delivered and fully paid and non-assessable; (ii) take all such action as
may be necessary to comply with any applicable requirements of the Securities
Act of 1933, as amended, or the Securities Exchange Act, and the rules and
regulations thereunder, and any other applicable law, rule or regulation, in
connection with the issuance of any shares upon

                                       7
<PAGE>

exercise of Rights; and (iii) pay when due and payable any and all federal and
state transfer taxes and charges which may be payable in respect of the original
issuance or delivery of the Rights Certificates or of any shares issued upon the
exercise of Rights, provided that the Company shall not be required to pay any
transfer tax or charge which may be payable in respect of any transfer involved
in the transfer or delivery of Rights Certificates or the issuance or delivery
of certificates for shares in a name other than that of the holder of the Rights
being transferred or exercised.

      2.4 ADJUSTMENTS TO EXERCISE PRICE; NUMBER OF RIGHTS. (a) In the event the
Company shall at any time after the Record Time and prior to the Separation Time
(i) declare or pay a dividend on Common Stock payable in Common Stock, (ii)
subdivide the outstanding Common Stock or (iii) combine the outstanding Common
Stock into a smaller number of shares of Common Stock, (x) the Exercise Price in
effect after such adjustment will be equal to the Exercise Price in effect
immediately prior to such adjustment divided by the number of shares of Common
Stock (the "Expansion Factor") that a holder of one share of Common Stock
immediately prior to such dividend, subdivision or combination would hold
thereafter as a result thereof and (y) each Right held prior to such adjustment
will become that number of Rights equal to the Expansion Factor, and the
adjusted number of Rights will be deemed to be distributed among the shares of
Common Stock with respect to which the original Rights were associated (if they
remain outstanding) and the shares issued in respect of such dividend,
subdivision or combination, so that each such share of Common Stock will have
exactly one Right associated with it. Each adjustment made pursuant to this
paragraph shall be made as of the payment or effective date for the applicable
dividend, subdivision or combination.

      In the event the Company shall at any time after the Record Time and prior
to the Separation Time issue any shares of Common Stock otherwise than in a
transaction referred to in the preceding paragraph, each such share of Common
Stock so issued shall automatically have one new Right associated with it, which
Right shall be evidenced by the certificate representing such share. To the
extent provided in Section 5.3, Rights shall be issued by the Company in respect
of shares of Common Stock that are issued or sold by the Company after the
Separation Time.

      (b) In the event the Company shall at any time after the Record Time and
prior to the Separation Time issue or distribute any securities or assets in
respect of, in lieu of or in exchange for Common Stock (other than pursuant to a
regular periodic cash dividend or a dividend paid solely in Common Stock)
whether by dividend, in a reclassification or recapitalization (including any
such transaction involving a merger, consolidation or share exchange), or
otherwise, the Company shall make such adjustments, if any, in the Exercise
Price, number of Rights and/or securities or other property purchasable upon
exercise of Rights as the Board of Directors of the Company, in its sole
discretion, may deem to be appropriate under the circumstances in order to
adequately protect the interests of the holders of Rights generally, and the
Company and the Rights Agent shall amend this Agreement as necessary to provide
for such adjustments.

      (c) Each adjustment to the Exercise Price made pursuant to this Section
2.4 shall be calculated to the nearest cent. Whenever an adjustment to the
Exercise Price is made pursuant to this Section 2.4, the Company shall (i)
promptly prepare a certificate setting forth such

                                       8
<PAGE>

adjustment and a brief statement of the facts accounting for such adjustment and
(ii) promptly file with the Rights Agent and with each transfer agent for the
Common Stock a copy of such certificate.

      (d) Rights certificates shall represent the securities purchasable under
the terms of this Agreement, including any adjustment or change in the
securities purchasable upon exercise of the Rights, even though such
certificates may continue to express the securities purchasable at the time of
issuance of the initial Rights Certificates.

      2.5 DATE ON WHICH EXERCISE IS EFFECTIVE. Each person in whose name any
certificate for shares is issued upon the exercise of Rights shall for all
purposes be deemed to have become the holder of record of the shares represented
thereby on the date upon which the Rights Certificate evidencing such Rights was
duly surrendered and payment of the Exercise Price for such Rights (and any
applicable taxes and other governmental charges payable by the exercising holder
hereunder) was made; PROVIDED, HOWEVER, that if the date of such surrender and
payment is a date upon which the stock transfer books of the Company are closed,
such person shall be deemed to have become the record holder of such shares on,
and such certificate shall be dated, the next succeeding Business Day on which
the stock transfer books of the Company are open.

      2.6 EXECUTION, AUTHENTICATION, DELIVERY AND DATING OF RIGHTS CERTIFICATES.
(a) The Rights Certificates shall be executed on behalf of the Company by its
Chairman of the Board, President or one of its Vice Presidents, under its
corporate seal reproduced thereon attested by its Secretary or one of its
Assistant Secretaries. The signature of any of these officers on the Rights
Certificates may be manual or facsimile.

      Rights Certificates bearing the manual or facsimile signatures of
individuals who were at any time the proper officers of the Company shall bind
the Company, notwithstanding that such individuals or any of them have ceased to
hold such offices prior to the countersignature and delivery of such Rights
Certificates.

      Promptly after the Separation Time, the Company will notify the Rights
Agent of such Separation Time and will deliver Rights Certificates executed by
the Company to the Rights Agent for countersignature, and, subject to Section
3.1(b), the Rights Agent shall manually countersign and deliver such Rights
Certificates to the holders of the Rights pursuant to Section 2.3(c) hereof. No
Rights Certificate shall be valid for any purpose unless manually countersigned
by the Rights Agent.

      (b) Each Rights Certificate shall be dated the date of countersignature
thereof.

      2.7 REGISTRATION, REGISTRATION OF TRANSFER AND EXCHANGE. (a) After the
Separation Time, the Company will cause to be kept a register (the "Rights
Register") in which, subject to such reasonable regulations as it may prescribe,
the Company will provide for the registration and transfer of Rights. The Rights
Agent is hereby appointed "Rights Registrar" for the purpose of maintaining the
Rights Register for the Company and registering Rights and transfers of Rights
after the Separation Time as herein provided. In the event that the Rights Agent
shall cease to be the Rights Registrar, the Rights Agent will have the right to
examine the Rights Register at all reasonable times after the Separation Time.

                                       9
<PAGE>

      After the Separation Time and prior to the Expiration Time, upon surrender
for registration of transfer or exchange of any Rights Certificate, and subject
to the provisions of Section 2.7(c) and (d), the Company will execute, and the
Rights Agent will countersign and deliver, in the name of the holder or the
designated transferee or transferees, as required pursuant to the holder's
instructions, one or more new Rights Certificates evidencing the same aggregate
number of Rights as did the Rights Certificate so surrendered.

      (b) Except as otherwise provided in Section 3.1(b), all Rights issued upon
any registration of transfer or exchange of Rights Certificates shall be the
valid obligations of the Company, and such Rights shall be entitled to the same
benefits under this Agreement as the Rights surrendered upon such registration
of transfer or exchange.

      (c) Every Rights Certificate surrendered for registration of transfer or
exchange shall be duly endorsed, or be accompanied by a written instrument of
transfer in form satisfactory to the Company or the Rights Agent, as the case
may be, duly executed by the holder thereof or such holder's attorney duly
authorized in writing. As a condition to the issuance of any new Rights
Certificate under this Section 2.7, the Company may require the payment of a sum
sufficient to cover any tax or other governmental charge that may be imposed in
relation thereto.

      (d) The Company shall not be required to register the transfer or exchange
of any Rights after such Rights have become void under Section 3.1(b), been
exchanged under Section 3.1(c) or been redeemed or terminated under Section 5.1.

      2.8 MUTILATED, DESTROYED, LOST AND STOLEN RIGHTS CERTIFICATES. (a) If any
mutilated Rights Certificate is surrendered to the Rights Agent prior to the
Expiration Time, then, subject to Sections 3.1(b), 3.1(c) and 5.1, the Company
shall execute and the Rights Agent shall countersign and deliver in exchange
therefor a new Rights Certificate evidencing the same number of Rights as did
the Rights Certificate so surrendered.

      (b) If there shall be delivered to the Company and the Rights Agent prior
to the Expiration Time (i) evidence to their satisfaction of the destruction,
loss or theft of any Rights Certificate, and (ii) such security or indemnity as
may be required by them to save each of them and any of their agents harmless,
then, subject to Sections 3.1(b), 3.1(c) and 5.1 and in the absence of notice to
the Company or the Rights Agent that such Rights Certificate has been acquired
by a bona fide purchaser, the Company shall execute and upon its request the
Rights Agent shall countersign and deliver, in lieu of any such destroyed, lost
or stolen Rights Certificate, a new Rights Certificate evidencing the same
number of Rights as did the Rights Certificate so destroyed, lost or stolen.

      (c) As a condition to the issuance of any new Rights Certificate under
this Section 2.8, the Company may require the payment of a sum sufficient to
cover any tax or other governmental charge that may be imposed in relation
thereto and any other expenses (including the fees and expenses of the Rights
Agent) connected therewith.

      (d) Every new Rights Certificate issued pursuant to this Section 2.8 in
lieu of any destroyed, lost or stolen Rights Certificate shall evidence an
original additional contractual obligation of the Company, whether or not the
destroyed, lost or stolen Rights Certificate shall

                                       10
<PAGE>

be at any time enforceable by anyone, and, subject to Section 3.1(b), shall be
entitled to all the benefits of this Agreement equally and proportionately with
any and all other Rights duly issued hereunder.

      2.9 PERSONS DEEMED OWNERS. Prior to due presentment of a Rights
Certificate (or, prior to the Separation Time, the associated Common Stock
certificate) for registration of transfer, the Company, the Rights Agent and any
agent of the Company or the Rights Agent may deem and treat the person in whose
name such Rights Certificate (or, prior to the Separation Time, such Common
Stock certificate) is registered as the absolute owner thereof and of the Rights
evidenced thereby for all purposes whatsoever, including the payment of the
Redemption Price and neither the Company nor the Rights Agent shall be affected
by any notice to the contrary. As used in this Agreement, unless the context
otherwise requires, the term "holder" of any Rights shall mean the registered
holder of such Rights (or, prior to the Separation Time, the associated shares
of Common Stock).

      2.10 DELIVERY AND CANCELLATION OF CERTIFICATES. All Rights Certificates
surrendered upon exercise or for registration of transfer or exchange shall, if
surrendered to any person other than the Rights Agent, be delivered to the
Rights Agent and, in any case, shall be promptly cancelled by the Rights Agent.
The Company may at any time deliver to the Rights Agent for cancellation any
Rights Certificates previously countersigned and delivered here under which the
Company may have acquired in any manner whatsoever, and all Rights Certificates
so delivered shall be promptly cancelled by the Rights Agent. No Rights
Certificates shall be countersigned in lieu of or in exchange for any Rights
Certificates cancelled as provided in this Section 2.10, except as expressly
permitted by this Agreement. The Rights Agent shall return all cancelled Rights
Certificates to the Company.

      2.11 AGREEMENT OF RIGHTS HOLDERS. Every holder of Rights by accepting the
same consents and agrees with the Company and the Rights Agent and with every
other holder of Rights that:

      (a) prior to the Separation Time, each Right will be transferable only
together with, and will be transferred by a transfer of, the associated share of
Common Stock;

      (b) after the Separation Time, the Rights Certificates will be
transferable only on the Rights Register as provided herein;

      (c) prior to due presentment of a Rights Certificate (or, prior to the
Separation Time, the associated Common Stock certificate) for registration of
transfer, the Company, the Rights Agent and any agent of the Company or the
Rights Agent may deem and treat the person in whose name the Rights Certificate
(or, prior to the Separation Time, the associated Common Stock certificate) is
registered as the absolute owner thereof and of the Rights evidenced thereby for
all purposes whatsoever, and neither the Company nor the Rights Agent shall be
affected by any notice to the contrary;

      (d) Rights beneficially owned by certain Persons will, under the
circumstances set forth in Section 3.1(b), become void; and

                                       11
<PAGE>

      (e) this Agreement may be supplemented or amended from time to time
pursuant to Section 2.4(b) or 5.4 hereof.

                                  ARTICLE III

         ADJUSTMENTS TO THE RIGHTS IN THE EVENT OF CERTAIN TRANSACTIONS

      3.1 FLIP-IN. (a) In the event that prior to the Expiration Time a Flip-in
Date shall occur, except as provided in this Section 3.1, each Right shall
constitute the right to purchase from the Company, upon exercise thereof in
accordance with the terms hereof (but subject to Section 5.10), that number of
shares of Common Stock having an aggregate Market Price on the Stock Acquisition
Date equal to twice the Exercise Price for an amount in cash equal to the
Exercise Price (such right to be appropriately adjusted in order to protect the
interests of the holders of Rights generally in the event that on or after such
Stock Acquisition Date an event of a type analogous to any of the events
described in Section 2.4(a) or (b) shall have occurred with respect to the
Common Stock).

      (b) Notwithstanding the foregoing, any Rights that are or were
Beneficially Owned on or after the Stock Acquisition Date by an Acquiring Person
or an Affiliate or Associate thereof or by any transferee, direct or indirect,
of any of the foregoing shall become void and any holder of such Rights
(including transferees) shall thereafter have no right to exercise or transfer
such Rights under any provision of this Agreement. If any Rights Certificate is
presented for assignment or exercise and the Person presenting the same will not
complete the certification set forth at the end of the form of assignment or
notice of election to exercise and provide such additional evidence of the
identity of the Beneficial Owner and its Affiliates and Associates (or former
Beneficial Owners and their Affiliates and Associates) as the Company shall
reasonably request, then the Company shall be entitled conclusively to deem the
Beneficial Owner thereof to be an Acquiring Person or an Affiliate or Associate
thereof or a transferee of any of the foregoing and accordingly will deem the
Rights evidenced thereby to be void and not transferable or exercisable.

      (c) The Board of Directors of the Company may, at its option, at any time
after a Flip-in Date and prior to the time that an Acquiring Person becomes the
Beneficial Owner of more than 50% of the outstanding shares of Common Stock,
elect to exchange all (but not less than all) of the then outstanding Rights
(which shall not include Rights that have become void pursuant to the provisions
of Section 3.1(b)) for shares of Common Stock at an exchange ratio of one share
of Common Stock per Right, appropriately adjusted in order to protect the
interests of holders of Rights generally in the event that after the Separation
Time an event of a type analogous to any of the events described in Section
2.4(a) or (b) shall have occurred with respect to the Common Stock (such
exchange ratio, as adjusted from time to time, being hereinafter referred to as
the "Exchange Ratio").

      Immediately upon the action of the Board of Directors of the Company
electing to exchange the Rights, without any further action and without any
notice, the right to exercise the Rights will terminate and each Right (other
than Rights that have become void pursuant to Section 3.1(b)) will thereafter
represent only the right to receive a number of shares of Common

                                       12
<PAGE>

Stock equal to the Exchange Ratio. Promptly after the action of the Board of
Directors electing to exchange the Rights, the Company shall give notice thereof
(specifying the steps to be taken to receive shares of Common Stock in exchange
for Rights) to the Rights Agent and the holders of the Rights (other than Rights
that have become void pursuant to Section 3.1(b)) outstanding immediately prior
thereto by mailing such notice in accordance with Section 5.9.

      Each Person in whose name any certificate for shares is issued upon the
exchange of Rights pursuant to this Section 3.1(c) or Section 3.1(d) shall for
all purposes be deemed to have become the holder of record of the shares
represented thereby on, and such certificate shall be dated, the date upon which
the Rights Certificate evidencing such Rights was duly surrendered and payment
of any applicable taxes and other governmental charges payable by the holder was
made; PROVIDED, HOWEVER, that if the date of such surrender and payment is a
date upon which the stock transfer books of the Company are closed, such Person
shall be deemed to have become the record holder of such shares on, and such
certificate shall be dated, the next succeeding Business Day on which the stock
transfer books of the Company are open.

      (d) Whenever the Company shall become obligated under Section 3.1(a) or
(c) to issue shares of Common Stock upon exercise of or in exchange for Rights,
the Company, at its option, may substitute therefor shares of Preferred Stock,
at a ratio of one one-hundredth of a share of Preferred Stock for each share of
Common Stock so issuable.

      (e) In the event that there shall not be sufficient treasury shares or
authorized but unissued shares of Common Stock or Preferred Stock of the Company
to permit the exercise or exchange in full of the Rights in accordance with
Section 3.1(a) or (c), the Company shall either (i) call a meeting of
stockholders seeking approval to cause sufficient additional shares to be
authorized (provided that if such approval is not obtained the Company will take
the action specified in clause (ii) of this sentence) or (ii) take such action
as shall be necessary to ensure and provide, to the extent permitted by
applicable law and any agreements or instruments in effect on the Stock
Acquisition Date to which it is a party, that each Right shall thereafter
constitute the right to receive, (x) at the Company's option, either (A) in
return for the Exercise Price, debt or equity securities or other assets (or a
combination thereof) having a fair value equal to twice the Exercise Price, or
(B) without payment of consideration (except as otherwise required by applicable
law), debt or equity securities or other assets (or a combination thereof)
having a fair value equal to the Exercise Price, or (y) if the Board of
Directors of the Company elects to exchange the Rights in accordance with
Section 3.1(c), debt or equity securities or other assets (or a combination
thereof) having a fair value equal to the product of the Market Price of a share
of Common Stock on the Flip-in Date times the Exchange Ratio in effect on the
Flip-in Date, where in any case set forth in (x) or (y) above the fair value of
such debt or equity securities or other assets shall be as determined in good
faith by the Board of Directors of the Company, after consultation with a
nationally recognized investment banking firm.

      3.2 FLIP-OVER. (a) Prior to the Expiration Time, the Company shall not
enter into any agreement with respect to, consummate or permit to occur any
Flip-over Transaction or Event unless and until it shall have entered into a
supplemental agreement with the Flip-over Entity, for the benefit of the holders
of the Rights, providing that, upon consummation or occurrence of the Flip-over
Transaction or Event (i) each Right shall thereafter constitute the right to
purchase

                                       13
<PAGE>

from the Flip-over Entity, upon exercise thereof in accordance with the terms
hereof, that number of shares of Flip-over Stock of the Flip-over Entity having
an aggregate Market Price on the date of consummation or occurrence of such
Flip-over Transaction or Event equal to twice the Exercise Price for an amount
in cash equal to the Exercise Price (such right to be appropriately adjusted in
order to protect the interests of the holders of Rights generally in the event
that after such date of consummation or occurrence an event of a type analogous
to any of the events described in Section 2.4(a) or (b) shall have occurred with
respect to the Flip-over Stock) and (ii) the Flip-over Entity shall thereafter
be liable for, and shall assume, by virtue of such Flip-over Transaction or
Event and such supplemental agreement, all the obligations and duties of the
Company pursuant to this Agreement. The provisions of this Section 3.2 shall
apply to successive Flip-over Transactions or Events.

      (b) Prior to the Expiration Time, unless the Rights will be redeemed
pursuant to Section 5.1 hereof in connection therewith, the Company shall not
enter into any agreement with respect to, consummate or permit to occur any
Flip-over Transaction or Event if at the time thereof there are any rights,
warrants or securities outstanding or any other arrangements, agreements or
instruments that would eliminate or otherwise diminish in any material respect
the benefits intended to be afforded by this Agreement to the holders of Rights
upon consummation of such transaction.

                                   ARTICLE IV

                                THE RIGHTS AGENT

      4.1 GENERAL. (a) The Company hereby appoints the Rights Agent to act as
agent for the Company in accordance with the terms and conditions hereof, and
the Rights Agent hereby accepts such appointment. The Company agrees to pay to
the Rights Agent reasonable compensation for all services rendered by it
hereunder and, from time to time, on demand of the Rights Agent, its reasonable
expenses and counsel fees and other disbursements incurred in the administration
and execution of this Agreement and the exercise and performance of its duties
hereunder. The Company also agrees to indemnify the Rights Agent for, and to
hold it harmless against, any loss, liability, or expense, incurred without
negligence, bad faith or willful misconduct on the part of the Rights Agent, for
anything done or omitted to be done by the Rights Agent in connection with the
acceptance and administration of this Agreement, including the costs and
expenses of defending against any claim of liability.

      (b) The Rights Agent shall be protected and shall incur no liability for
or in respect of any action taken, suffered or omitted by it in connection with
its administration of this Agreement in reliance upon any certificate for
securities purchasable upon exercise of Rights, Rights Certificate, certificate
for other securities of the Company, instrument of assignment or transfer, power
of attorney, endorsement, affidavit, letter, notice, direction, consent,
certificate, statement, or other paper or document believed by it to be genuine
and to be signed, executed and, where necessary, verified or acknowledged, by
the proper person or persons.

      4.2 MERGER OR CONSOLIDATION OR CHANGE OF NAME OF RIGHTS AGENT. (b) Any
corporation into which the Rights Agent or any successor Rights Agent may be
merged or with

                                       14
<PAGE>

which it may be consolidated, or any corporation resulting from any merger or
consolidation to which the Rights Agent or any successor Rights Agent is a
party, or any corporation succeeding to the shareholder services business of the
Rights Agent or any successor Rights Agent, will be the successor to the Rights
Agent under this Agreement without the execution or filing of any paper or any
further act on the part of any of the parties hereto, provided that such
corporation would be eligible for appointment as a successor Rights Agent under
the provisions of Section 4.4 hereof. In case at the time such successor Rights
Agent succeeds to the agency created by this Agreement any of the Rights
Certificates have been countersigned but not delivered, any such successor
Rights Agent may adopt the countersignature of the predecessor Rights Agent and
deliver such Rights Certificates so countersigned; and in case at that time any
of the Rights Certificates have not been countersigned, any successor Rights
Agent may countersign such Rights Certificates either in the name of the
predecessor Rights Agent or in the name of the successor Rights Agent; and in
all such cases such Rights Certificates will have the full force provided in the
Rights Certificates and in this Agreement.

      (b) In case at any time the name of the Rights Agent is changed and at
such time any of the Rights Certificates shall have been countersigned but not
delivered, the Rights Agent may adopt the countersignature under its prior name
and deliver Rights Certificates so countersigned; and in case at that time any
of the Rights Certificates shall not have been countersigned, the Rights Agent
may countersign such Rights Certificates either in its prior name or in its
changed name; and in all such cases such Rights Certificates shall have the full
force provided in the Rights Certificates and in this Agreement.

      4.3 DUTIES OF RIGHTS AGENT. The Rights Agent undertakes the duties and
obligations imposed by this Agreement upon the following terms and conditions,
by all of which the Company and the holders of Rights Certificates, by their
acceptance thereof, shall be bound:

      (a) The Rights Agent may consult with legal counsel (who may be legal
counsel for the Company), and the opinion of such counsel will be full and
complete authorization and protection to the Rights Agent as to any action taken
or omitted by it in good faith and in accordance with such opinion.

      (b) Whenever in the performance of its duties under this Agreement the
Rights Agent deems it necessary or desirable that any fact or matter be proved
or established by the Company prior to taking or suffering any action hereunder,
such fact or matter (unless other evidence in respect thereof be herein
specifically prescribed) may be deemed to be conclusively proved and established
by a certificate signed by a person believed by the Rights Agent to be the
Chairman of the Board, the President or any Vice President and by the Treasurer
or any Assistant Treasurer or the Secretary or any Assistant Secretary of the
Company and delivered to the Rights Agent; and such certificate will be full
authorization to the Rights Agent for any action taken or suffered in good faith
by it under the provisions of this Agreement in reliance upon such certificate.

      (c) The Rights Agent will be liable hereunder only for its own gross
negligence, bad faith or willful misconduct.

                                       15
<PAGE>

      (d) The Rights Agent will not be liable for or by reason of any of the
statements of fact or recitals contained in this Agreement or in the
certificates for securities purchasable upon exercise of Rights or the Rights
Certificates (except its countersignature thereof) or be required to verify the
same, but all such statements and recitals are and will be deemed to have been
made by the Company only.

      (e) The Rights Agent will not be under any responsibility in respect of
the validity of this Agreement or the execution and delivery hereof (except the
due authorization, execution and delivery hereof by the Rights Agent) or in
respect of the validity or execution of any certificate for securities
purchasable upon exercise of Rights or Rights Certificate (except its
countersignature thereof); nor will it be responsible for any breach by the
Company of any covenant or condition contained in this Agreement or in any
Rights Certificate; nor will it be responsible for any change in the
exercisability of the Rights (including the Rights becoming void pursuant to
Section 3.1(b) hereof) or any adjustment required under the provisions of
Section 2.4, 3.1 or 3.2 hereof or responsible for the manner, method or amount
of any such adjustment or the ascertaining of the existence of facts that would
require any such adjustment (except with respect to the exercise of Rights after
receipt of the certificate contemplated by Section 2.4 describing any such
adjustment); nor will it by any act hereunder be deemed to make any
representation or warranty as to the authorization or reservation of any
securities purchasable upon exercise of Rights or any Rights or as to whether
any securities purchasable upon exercise of Rights will, when issued, be duly
and validly authorized, executed, issued and delivered and fully paid and
non-assessable.

      (f) The Company agrees that it will perform, execute, acknowledge and
deliver or cause to be performed, executed, acknowledged and delivered all such
further and other acts, instruments and assurances as may reasonably be required
by the Rights Agent for the carrying out or performing by the Rights Agent of
the provisions of this Agreement.

      (g) The Rights Agent is hereby authorized and directed to accept
instructions with respect to the performance of its duties hereunder from any
person believed by the Rights Agent to be the Chairman of the Board, the
President or any Vice President or the Secretary or any Assistant Secretary or
the Treasurer or any Assistant Treasurer of the Company, and to apply to such
persons for advice or instructions in connection with its duties, and it shall
not be liable for any action taken or suffered by it in good faith in accordance
with instructions of any such person.

      (h) The Rights Agent and any stockholder, director, officer or employee of
the Rights Agent may buy, sell or deal in Common Stock, Rights or other
securities of the Company or become pecuniarily interested in any transaction in
which the Company may be interested, or contract with or lend money to the
Company or otherwise act as fully and freely as though it were not Rights Agent
under this Agreement. Nothing herein shall preclude the Rights Agent from acting
in any other capacity for the Company or for any other legal entity.

      (i) The Rights Agent may execute and exercise any of the rights or powers
hereby vested in it or perform any duty hereunder either itself or by or through
its attorneys or agents, and the Rights Agent will not be answerable or
accountable for any act, default, neglect or

                                       16
<PAGE>

misconduct of any such attorneys or agents or for any loss to the Company
resulting from any such act, default, neglect or misconduct, provided reasonable
care was exercised in the selection and continued employment thereof.

      4.4 CHANGE OF RIGHTS AGENT. The Rights Agent may resign and be discharged
from its duties under this Agreement upon 90 days' notice (or such lesser notice
as is acceptable to the Company) in writing mailed to the Company and to each
transfer agent of Common Stock by registered or certified mail, and to the
holders of the Rights in accordance with Section 5.9. The Company may remove the
Rights Agent upon 30 days' notice in writing, mailed to the Rights Agent and to
each transfer agent of the Common Stock by registered or certified mail, and to
the holders of the Rights in accordance with Section 5.9. If the Rights Agent
should resign or be removed or otherwise become incapable of acting, the Company
will appoint a successor to the Rights Agent. If the Company fails to make such
appointment within a period of 30 days after such removal or after it has been
notified in writing of such resignation or incapacity by the resigning or
incapacitated Rights Agent or by the holder of any Rights (which holder shall,
with such notice, submit such holder's Rights Certificate for inspection by the
Company), then the holder of any Rights may apply to any court of competent
jurisdiction for the appointment of a new Rights Agent. Any successor Rights
Agent, whether appointed by the Company or by such a court, shall be a
corporation organized and doing business under the laws of the United States or
any State of the United States, in good standing, which is authorized under such
laws to exercise the powers of the Rights Agent contemplated by this Agreement
and is subject to supervision or examination by federal or state authority.
After appointment, the successor Rights Agent will be vested with the same
powers, rights, duties and responsibilities as if it had been originally named
as Rights Agent without further act or deed; but the predecessor Rights Agent
shall deliver and transfer to the successor Rights Agent any property at the
time held by it hereunder, and execute and deliver any further assurance,
conveyance, act or deed necessary for the purpose. Not later than the effective
date of any such appointment, the Company will file notice thereof in writing
with the predecessor Rights Agent and each transfer agent of the Common Stock,
and mail a notice thereof in writing to the holders of the Rights. Failure to
give any notice provided for in this Section 4.4, however, or any defect
therein, shall not affect the legality or validity of the resignation or removal
of the Rights Agent or the appointment of the successor Rights Agent, as the
case may be.

                                   ARTICLE V

                                  MISCELLANEOUS

      5.1 REDEMPTION. (a) The Board of Directors of the Company may, at its
option, at any time prior to the close of business on the Flip-in Date, elect to
redeem all (but not less than all) of the then-outstanding Rights at the
Redemption Price, and the Company, at its option, may pay the Redemption Price
either in cash or shares of Common Stock or other securities of the Company
deemed by the Board of Directors, in the exercise of its sole discretion, to be
at least equivalent in value to the Redemption Price.

      (b) Immediately upon the action of the Board of Directors of the Company
electing to redeem the Rights (or, if the resolution of the Board of Directors
electing to redeem the Rights

                                       17
<PAGE>

states that the redemption will not be effective until the occurrence of a
specified future time or event, upon the occurrence of such future time or
event), without any further action and without any notice, the right to exercise
the Rights will terminate and each Right will thereafter represent only the
right to receive the Redemption Price in cash or securities, as determined by
the Board of Directors. Promptly after the Rights are redeemed, the Company
shall give notice of such redemption to the Rights Agent and the holders of the
then-outstanding Rights by mailing such notice in accordance with Section 5.9.

      5.2 EXPIRATION. The Rights and this Agreement shall expire at the
Expiration Time and no Person shall have any rights pursuant to this Agreement
or any Right after the Expiration Time, except, if the Rights are exchanged or
redeemed, as provided in Section 3.1 or 5.1 hereof

      5.3 ISSUANCE OF NEW RIGHTS CERTIFICATES. Notwithstanding any of the
provisions of this Agreement or of the Rights to the contrary, the Company may,
at its option, issue new Rights Certificates evidencing Rights in such form as
may be approved by its Board of Directors to reflect any adjustment or change in
the number or kind or class of shares of stock purchasable upon exercise of
Rights made in accordance with the provisions of this Agreement. In addition, in
connection with the issuance or sale of shares of Common Stock by the Company
following the Separation Time and prior to the Expiration Time pursuant to the
terms of securities convertible or redeemable into shares of Common Stock or to
options, in each case issued or granted prior to, and outstanding at, the
Separation Time, the Company shall issue to the holders of such shares of Common
Stock, Rights Certificates representing the appropriate number of Rights in
connection with the issuance or sale of such shares of Common Stock; PROVIDED,
HOWEVER, in each case, (i) no such Rights Certificate shall be issued, if, and
to the extent that, the Company shall be advised by counsel that such issuance
would create a significant risk of material adverse tax consequences to the
Company or to the Person to whom such Rights Certificates would be issued, (ii)
no such Rights Certificates shall be issued if, and to the extent that,
appropriate adjustment shall have otherwise been made in lieu of the issuance
thereof, and (iii) the Company shall have no obligation to distribute Rights
Certificates to any Acquiring Person or Affiliate or Associate of an Acquiring
Person or any transferee of any of the foregoing.

      5.4 SUPPLEMENTS AND AMENDMENTS. The Company and the Rights Agent may from
time to time supplement or amend this Agreement without the approval of any
holders of Rights (i) prior to the close of business on the Flip-in Date, in any
respect and (ii) after the close of business on the Flip-in Date, to make any
changes that the Company may deem necessary or desirable and which shall not
materially adversely affect the interests of the holders of Rights generally or
in order to cure any ambiguity or to correct or supplement any provision
contained herein which may be inconsistent with any other provisions herein or
otherwise defective. The Rights Agent will duly execute and deliver any
supplement or amendment hereto requested by the Company which satisfies the
terms of the preceding sentence.

      5.5 FRACTIONAL SHARES. If the Company elects not to issue certificates
representing fractional shares upon exercise or redemption of Rights, the
Company shall, in lieu thereof, in the sole discretion of the Board of
Directors, either (a) evidence such fractional shares by depositary receipts
issued pursuant to an appropriate agreement between the Company and a depositary
selected by it, providing that each holder of a depositary receipt shall have
all of the

                                       18
<PAGE>

rights, privileges and preferences to which such holder would be entitled as a
beneficial owner of such fractional share, or (b) sell such shares on behalf of
the holders of Right and pay to the registered holder of such Rights the
appropriate fraction of price per share received upon such sale.

      5.6 RIGHTS OF ACTION. Subject to the terms of this Agreement (including
Section 3.1(b)), rights of action in respect of this Agreement, other than
rights of action vested solely in the Rights Agent, are vested in the respective
holders of the Rights; and any holder of any Rights, without the consent of the
Rights Agent or of the holder of any other Rights, may, on such holder's own
behalf and for such holder's own benefit and the benefit of other holders of
Rights, enforce, and may institute and maintain any suit, action or proceeding
against the Company to enforce, or otherwise act in respect of, such holder's
right to exercise such holder's Rights in the manner provided in such holder's
Rights Certificate and in this Agreement. Without limiting the foregoing or any
remedies available to the holders of Rights, it is specifically acknowledged
that the holders of Rights would not have an adequate remedy at law for any
breach of this Agreement and will be entitled to specific performance of the
obligations under, and injunctive relief against actual or threatened violations
of, the obligations of any Person subject to this Agreement.

      5.7 HOLDER OF RIGHTS NOT DEEMED A STOCKHOLDER. No holder, as such, of any
Rights shall be entitled to vote, receive dividends or be deemed for any purpose
the holder of shares or any other securities which may at any time be issuable
on the exercise of such Rights, nor shall anything contained herein or in any
Rights Certificate be construed to confer upon the holder of any Rights, as
such, any of the rights of a stockholder of the Company or any right to vote for
the election of directors or upon any matter submitted to stockholders at any
meeting thereof, or to give or withhold consent to any corporate action, or to
receive notice of meetings or other actions affecting stockholders (except as
provided in Section 5.8 hereof), or to receive dividends or subscription rights,
or otherwise, until such Rights shall have been exercised or exchanged in
accordance with the provisions hereof.

      5.8 NOTICE OF PROPOSED ACTIONS. In case the Company shall propose after
the Separation Time and prior to the Expiration Time (i) to effect or permit
occurrence of any Flip-over Transaction or Event or (ii) to effect the
liquidation, dissolution or winding up of the Company, then, in each such case,
the Company shall give to each holder of a Right, in accordance with Section 5.9
hereof, a notice of such proposed action, which shall specify the date on which
such Flip-over Transaction or Event, liquidation, dissolution, or winding up is
to take place, and such notice shall be so given at least 20 Business Days prior
to the date of the taking of such proposed action.

      5.9 NOTICES. Notices or demands authorized or required by this Agreement
to be given or made by the Rights Agent or by the holder of any Rights to or on
the Company shall be sufficiently given or made if delivered or sent by
first-class mail, postage prepaid, addressed (until another address is filed in
writing with the Rights Agent) as follows:

                                       19
<PAGE>

            First Federal Financial Bancorp, Inc.
            415 Center Street
            Ironton, Ohio  45638
            Attention:  Secretary

      Any notice or demand authorized or required by this Agreement to be given
or made by the Company or by the holder of any Rights to or on the Rights Agent
shall be sufficiently given or made if delivered or sent by first-class mail,
postage prepaid, addressed (until another address is filed in writing with the
Company) as follows:

            Registrar and Transfer Company
            10 Commerce Drive
            Cranford, New Jersey  07016
            Attention:  Michael Jones

      Notices or demands authorized or required by this Agreement to be given or
made by the Company or the Rights Agent to or on the holder of any Rights shall
be sufficiently given or made if delivered or sent by first-class mail, postage
prepaid, addressed to such holder at the address of such holder as it appears
upon the registry books of the Rights Agent or, prior to the Separation Time, on
the registry books of the transfer agent for the Common Stock. Any notice which
is mailed in the manner herein provided shall be deemed given, whether or not
the holder receives the notice.

      5.10 SUSPENSION OF EXERCISABILITY. To the extent that the Company
determines in good faith that some action will or need be taken pursuant to
Section 3.1 or to comply with federal or state securities laws, the Company may
suspend the exercisability of the Rights for a reasonable period in order to
take such action or comply with such laws. In the event of any such suspension,
the Company shall issue as promptly as practicable a public announcement stating
that the exercisability or exchangeability of the Rights has been temporarily
suspended. Notice thereof pursuant to Section 5.9 shall not be required. Failure
to give a notice pursuant to the provisions of this Agreement shall not affect
the validity of any action taken hereunder.

      5.11 COSTS OF ENFORCEMENT. The Company agrees that if the Company or any
other Person the securities of which are purchasable upon exercise of Rights
fails to fulfill any of its obligations pursuant to this Agreement, then the
Company or such Person will reimburse the holder of any Rights for the costs and
expenses (including legal fees) incurred by such holder in actions to enforce
such holder's rights pursuant to any Rights or this Agreement.

      5.12 SUCCESSORS. All the covenants and provisions of this Agreement by or
for the benefit of the Company or the Rights Agent shall bind and inure to the
benefit of their respective successors and assigns hereunder.

      5.13 BENEFITS OF THIS AGREEMENT. Nothing in this Agreement shall be
construed to give to any Person other than the Company, the Rights Agent and the
holders of the Rights any legal or equitable right, remedy or claim under this
Agreement and this Agreement shall be for the sole and exclusive benefit of the
Company, the Rights Agent and the holders of the Rights.

                                       20
<PAGE>

      5.14 DETERMINATION AND ACTIONS BY THE BOARD OF DIRECTORS, ETC. (a) The
Board of Directors of the Company shall have the exclusive power and authority
to administer this Agreement and to exercise all rights and powers specifically
granted to the Board or to the Company, or as may be necessary or advisable in
the administration of this Agreement, including, without limitation, the right
and power to (i) interpret the provisions of this Agreement and (ii) make all
determinations deemed necessary or advisable for the administration of this
Agreement. All such actions, calculations, interpretations and determinations
(including, for purposes of clause (y) below, all omissions with respect to the
foregoing) which are done or made by the Board in good faith, shall (x) be
final, conclusive and binding on the Company, the Rights Agent, the holders of
the Rights and all other parties, and (y) not subject the Board of Directors of
the Company to any liability to the holders of the Rights.

      (b) In taking any action referred to in Section 5.14 (a), the Board of
Directors shall be entitled to consider, without limitation, the financial and
managerial resources and future prospects of an Acquiring Person, the possible
effects of the action on the business of the Company and its subsidiaries and on
the employees, customers, suppliers and creditors of the Company and its
subsidiaries and the effects on the communities in which the Company's and its
subsidiaries facilities are located.

      5.15 DESCRIPTIVE HEADINGS. Descriptive headings appear herein for
convenience only and shall not control or affect the meaning or construction of
any of the provisions hereof.

      5.16 GOVERNING LAW. THIS AGREEMENT AND EACH RIGHT ISSUED HEREUNDER SHALL
BE DEEMED TO BE A CONTRACT MADE UNDER THE LAWS OF THE STATE OF DELAWARE AND FOR
ALL PURPOSES SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF
SUCH STATE APPLICABLE TO CONTRACTS TO BE MADE AND PERFORMED ENTIRELY WITHIN SUCH
STATE.

      5.17 COUNTERPARTS. This Agreement may be executed in any number of
counterparts and each of such counterparts shall for all purposes be deemed to
be an original, and all such counterparts shall together constitute but one and
the same instrument.

      5.18 SEVERABILITY. If any term or provision hereof or the application
thereof to any circumstance shall, in any jurisdiction and to any extent, be
invalid or unenforceable, such term or provision shall be ineffective as to such
jurisdiction to the extent of such invalidity or unenforceability without
invalidating or rendering unenforceable the remaining terms and provisions
hereof or the application of such term or provision to circumstances other than
those as to which it is held invalid or unenforceable.

             [THE REMAINDER OF THIS PAGE INTENTIONALLY LEFT BLANK.]

                                       21
<PAGE>

      IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be
duly executed as of the date first above written.

                                    FIRST FEDERAL FINANCIAL BANCORP,
                                       INC.

                                    By:      /s/ Thomas D. Phillips
                                    Name:    Thomas D. Phillips
                                    Title:   Chairman

                                    By:      /s/ Edith M. Daniels
                                    Name:    Edith M. Daniels
                                    Title:   Secretary

                                    REGISTRAR AND TRANSFER COMPANY

                                    By:      /s/ William Tatler
                                    Name:    William Tatler
                                    Title:   Vice President

                                    By:      /s/ Nicole Giancaspro
                                    Name:    Nicole Giancaspro
                                    Title:   Vice President

                                       22
<PAGE>

                                                                       EXHIBIT A

                          [Form of Rights Certificate]

Certificate No. W-                                             __________ Rights

THE RIGHTS ARE SUBJECT TO REDEMPTION OR MANDATORY EXCHANGE, AT THE OPTION OF THE
COMPANY, ON THE TERMS SET FORTH IN THE RIGHTS AGREEMENT. RIGHTS BENEFICIALLY
OWNED BY ACQUIRING PERSONS OR AFFILIATES OR ASSOCIATES THEREOF (AS SUCH TERMS
ARE DEFINED IN THE RIGHTS AGREEMENT) OR TRANSFEREES OF ANY OF THE FOREGOING WILL
BE VOID.

                               Rights Certificate

                      FIRST FEDERAL FINANCIAL BANCORP, INC.

      This certifies that __________________________, or registered assigns, is
the registered holder of the number of Rights set forth above, each of which
entitles the registered holder thereof, subject to the terms, provisions and
conditions of the Stockholder Protection Rights Agreement, dated as of May 22,
2001 (as amended from time to time, the "Rights Agreement"), between First
Federal Financial Bancorp, Inc., a Delaware corporation (the "Company"), and
Registrar and Transfer Company, as Rights Agent (the "Rights Agent," which term
shall include any successor Rights Agent under the Rights Agreement), to
purchase from the Company at any time after the Separation Time (as such term is
defined in the Rights Agreement) and prior to the close of business on May 23,
2011, one one-hundredth of a fully paid share of Series A Junior Participating
Preferred Stock, par value $0.01 per share (the "Preferred Stock"), of the
Company (subject to adjustment as provided in the Rights Agreement) at the
Exercise Price referred to below, upon presentation and surrender of this Rights
Certificate with the Form of Election to Exercise duly executed at the principal
office of the Rights Agent in Cranford, New Jersey. The Exercise Price shall
initially be $40.00 per Right and shall be subject to adjustment in certain
events as provided in the Rights Agreement.

      In certain circumstances described in the Rights Agreement, the Rights
evidenced hereby may entitle the registered holder thereof to purchase
securities of an entity other than the Company or securities or assets of the
Company other than Preferred Stock, all as provided in the Rights Agreement.

      This Rights Certificate is subject to all of the terms, provisions and
conditions of the Rights Agreement, which terms, provisions and conditions are
hereby incorporated herein by reference and made a part hereof and to which
Rights Agreement reference is hereby made for a full description of the rights,
limitations of rights, obligations, duties and immunities hereunder of the
Rights Agent, the Company and the holders of the Rights Certificates. Copies of
the Rights Agreement are on file at the principal office of the Company and are
available without cost upon written request.

                                      A-1
<PAGE>

      This Rights Certificate, with or without other Rights Certificates, upon
surrender at the office of the Rights Agent designated for such purpose, may be
exchanged for another Rights Certificate or Rights Certificates of like tenor
evidencing an aggregate number of Rights equal to the aggregate number of Rights
evidenced by the Rights Certificate or Rights Certificates surrendered. If this
Rights Certificate shall be exercised in part, the registered holder shall be
entitled to receive, upon surrender hereof, another Rights Certificate or Rights
Certificates for the number of whole Rights not exercised.

      Subject to the provisions of the Rights Agreement, each Right evidenced by
this Certificate may be (a) redeemed by the Company under certain circumstances,
at its option, at a redemption price of $0.0l per Right or (b) exchanged by the
Company under certain circumstances, at its option, for one share of Common
Stock or one one-hundredth of a share of Preferred Stock per Right (or, in
certain cases, other securities or assets of the Company), subject in each case
to adjustment in certain events as provided in the Rights Agreement.

      No holder of this Rights Certificate, as such, shall be entitled to vote
or receive dividends or be deemed for any purpose the holder of any securities
which may at any time be issuable on the exercise hereof, nor shall any thing
contained in the Rights Agreement or herein be construed to confer upon the
holder hereof, as such, any of the rights of a stockholder of the Company or any
right to vote for the election of directors or upon any matter submitted to
stockholders at any meeting thereof, or to give or withhold consent to any
corporate action, or to receive notice of meetings or other actions affecting
stockholders (except as provided in the Rights Agreement), or to receive
dividends or subscription rights, or otherwise, until the Rights evidenced by
this Rights Certificate shall have been exercised or exchanged as provided in
the Rights Agreement.

      This Rights Certificate shall not be valid or obligatory for any purpose
until it shall have been countersigned by the Rights Agent.

                                      A-2
<PAGE>

      WITNESS the facsimile signature of the proper officers of the Company and
its corporate seal.

Date:  __________________________

ATTEST:                                    FIRST FEDERAL FINANCIAL
                                                 BANCORP, INC.

_____________________________              By:  __________________________
Edith M. Daniels                                Thomas D. Phillips
Secretary                                       Chairman

Countersigned:

By: _____________________
    Authorized Signature

                                      A-3
<PAGE>

                  [FORM OF REVERSE SIDE OF RIGHTS CERTIFICATE]

                               FORM OF ASSIGNMENT

(To be executed by the registered holder if such holder desires to transfer this
Rights Certificate.)

      FOR VALUE RECEIVED _____________________________________ hereby sells,
assigns and transfers unto ___________________________________________________

_____________
                  (Please print name and address of transferee)

this Rights Certificate, together with all right, title and interest therein,
and does hereby irrevocably constitute and appoint _________________________
Attorney, to transfer the within Rights Certificate on the books of the
within-named Company, with full power of substitution.

Dated:  __________________

Signature Guaranteed:          ______________________________________
                               Signature
                               (Signature must correspond to name as written
                               upon the face of this Rights Certificate in every
                               particular, without alteration or enlargement or
                               any change whatsoever)

      Signatures must be guaranteed by an eligible guarantor institution (banks,
stockbrokers, savings and loan associations and credit unions with membership in
an approved signature guarantee Medallion program), pursuant to SEC Rule
l7Ad-l5.

The undersigned hereby represents, for the benefit of all holders of Rights and
shares of Common Stock, that the Rights evidenced by this Rights Certificate are
not, and, to the knowledge of the undersigned, have never been, Beneficially
Owned by an Acquiring Person or an Affiliate or Associate thereof (as defined in
the Rights Agreement).

                                    ______________________________
                                    Signature

                                     NOTICE
                                     ------

      In the event the certification set forth above is not completed in
connection with a purported assignment, the Company will deem the Beneficial
Owner of the Rights evidenced by the enclosed Rights Certificate to be an
Acquiring Person or an Affiliate or Associate thereof (as defined in the Rights
Agreement) or a transferee of any of the foregoing and accordingly will deem the
Rights evidenced by such Rights Certificate to be void and not transferable or
exercisable.

                                      A-4
<PAGE>

                   [To be attached to each Rights Certificate]

                          FORM OF ELECTION TO EXERCISE

      (To be executed if holder desires to exercise the Rights Certificate.)

TO:   FIRST FEDERAL FINANCIAL BANCORP, INC.

      The undersigned hereby irrevocably elects to exercise the whole Rights
represented by the attached Rights Certificate to purchase the shares of Series
A Junior Participating Preferred Stock or Common Stock, as the case may be,
issuable upon the exercise of such Rights and requests that certificates for
such shares be issued in the name of:

                         __________________________________
                         Address:
                         __________________________________

                         __________________________________
                         Social Security or other Taxpayer
                         Identification Number:

                         __________________________________

      If such number of Rights shall not be all the Rights evidenced by this
Rights Certificate, a new Rights Certificate for the balance of such Rights
shall be registered in the name of and delivered to:

                         __________________________________
                         Address:
                         __________________________________

                         __________________________________
                         Social Security or other Taxpayer
                         Identification Number:

                         __________________________________

Dated:  _____________________

Signature Guaranteed:                     ______________________________
                                          Signature
                                          (Signature must correspond to name as
                                          written upon the face of this Rights
                                          Certificate in every particular,
                                          without alteration or enlargement or
                                          any change whatsoever)

      Signatures must be guaranteed by a member firm of a registered national
securities exchange, a member of the National Association of Securities Dealers,
Inc., or a commercial bank or trust company having an office or correspondent in
the United States.

                                      A-5
<PAGE>

      The undersigned hereby represents, for the benefit of all holders of
Rights and shares of Common Stock, that the Rights evidenced by the attached
Rights Certificate are not, and, to the knowledge of the undersigned, have never
been, Beneficially Owned by an Acquiring Person or an Affiliate or Associate
thereof (as defined in the Rights Agreement).

                                          _______________________________
                                          Signature

                                     NOTICE
                                     ------

      In the event the certification set forth above is not completed in
connection with a purported exercise, the Company will deem the Beneficial Owner
of the Rights evidenced by the attached Rights Certificate to be an Acquiring
Person or an Affiliate or Associate thereof (as defined in the Rights Agreement)
or a transferee of any of the foregoing and accordingly will deem the Rights
evidenced by such Rights Certificate to be void and not transferable or
exercisable.

                                      A-6
<PAGE>

                                                                       EXHIBIT B

               CERTIFICATE OF DESIGNATIONS, PREFERENCES AND RIGHTS
                OF SERIES A JUNIOR PARTICIPATING PREFERRED STOCK
                                       OF

                      FIRST FEDERAL FINANCIAL BANCORP, INC.

             PURSUANT TO SECTION 151 OF THE GENERAL CORPORATION LAW
                            OF THE STATE OF DELAWARE

      We, Thomas D. Phillips and Edith M. Daniels, being the Chairman and
Secretary, respectively, of First Federal Financial Bancorp, Inc., a corporation
organized and existing under the General Corporation Law of the State of
Delaware ("Company"), in accordance with the provisions of Sections 103 and 151
thereof, DO HEREBY CERTIFY:

      That pursuant to the authority conferred upon the Board of Directors by
the Certificate of Incorporation of the Company, the Board of Directors of the
Company at a meeting duly called and held on May 21, 2001, at which a quorum was
present and acting throughout, duly adopted the following resolution creating a
series of 10,000 shares of Preferred Stock, par value $.01 per share, designated
"Series A Junior Participating Preferred Stock":

            RESOLVED, that pursuant to the authority vested in the Board of
      Directors of the Company in accordance with the provisions of its
      Certificate of Incorporation, a series of preferred stock of the Company
      to be designated "Series A Junior Participating Preferred Stock," par
      value $.0 1 per share ("Preferred Stock"), be, and it hereby is, created,
      and the designations and amount thereof and the voting powers, preferences
      and relative, participating, optional and other special rights of the
      shares of such series, and the qualifications, limitations and
      restrictions thereof, are as follows:

SECTION 1.  DESIGNATION AND AMOUNT.

      The shares of such series shall be designated as "Series A Junior
Participating Preferred Stock," par value $.0l per share, and the number of
shares constituting such series shall be 10,000. Such number of shares may be
increased or decreased by resolution of the Board of Directors of the Company
("Board of Directors"); PROVIDED THAT, no decrease shall reduce the number of
shares of Series A Junior Participating Preferred Stock to a number less than
the number of shares then outstanding plus the number of shares reserved for
issuance upon the exercise of outstanding options, rights or warrants or upon
the conversion of any outstanding securities issued by the Company convertible
into Series A Junior Participating Preferred Stock.

                                      B-1
<PAGE>

SECTION 2.  DIVIDENDS AND DISTRIBUTIONS.

      (a) Subject to the rights of the holders of any shares of any series of
preferred stock (or any similar stock) ranking prior and superior to the Series
A Junior Participating Preferred Stock with respect to dividends, the holders of
shares of Series A Junior Participating Preferred Stock, in preference to the
holders of Common Stock, par value $.0l per share ("Common Stock"), of the
Company, and of any other stock, shall be entitled to receive, when, as and if
declared by the Board of Directors out of funds legally available for the
purpose, quarterly dividends payable in cash on the first day of March, June,
September and December in each year (each such date being referred to herein as
a "Quarterly Dividend Payment Date"), commencing on the first Quarterly Dividend
Payment Date after the first issuance of a share or fraction of a share of
Series A Junior Participating Preferred Stock, in an amount per share (rounded
to the nearest cent) equal to the greater of (a) $1.00 or (b) subject to the
provision for adjustment hereinafter set forth, 100 times the aggregate per
share amount of all cash dividends, and 100 times the aggregate per share amount
(payable in kind) of all non-cash dividends or other distributions, other than a
dividend payable in shares of Common Stock or a subdivision of the outstanding
shares of Common Stock (by reclassification or otherwise), declared on the
Common Stock since the immediately preceding Quarterly Dividend Payment Date or,
with respect to the first Quarterly Dividend Payment Date, since the first
issuance of any share or fraction of a share of Series A Junior Participating
Preferred Stock. In the event the Company shall at any time declare or pay any
dividend on the Common Stock payable in shares of Common Stock, or effect a
subdivision or combination or consolidation of the outstanding shares of Common
Stock (by reclassification or otherwise than by payment of a dividend in shares
of Common Stock) into a greater or lesser number of shares of Common Stock, then
in each such case the amount to which holders of shares of Series A Junior
Participating Preferred Stock were entitled immediately prior to such event
under clause (b) of the preceding sentence shall be adjusted by multiplying such
amount by a fraction, the numerator of which is the number of shares of Common
Stock outstanding immediately after such event and the denominator of which is
the number of shares of Common Stock that were outstanding immediately prior to
such event.

      (b) The Company shall declare a dividend or distribution on the Series A
Junior Participating Preferred Stock as provided in paragraph (a) of this
Section immediately after it declares a dividend or distribution on the Common
Stock (other than a dividend payable in shares of Common Stock); PROVIDED THAT,
in the event no dividend or distribution shall have been declared on the Common
Stock during the period between any Quarterly Dividend Payment Date and the next
subsequent Quarterly Dividend Payment Date, a dividend of $1.00 per share on the
Series A Junior Participating Preferred Stock shall nevertheless be payable on
such subsequent Quarterly Dividend Payment Data.

      (c) Dividends shall begin to accrue and be cumulative on outstanding
shares of Series A Junior Participating Preferred Stock from the Quarterly
Dividend Payment Date next preceding the date of issue of such shares, unless
the date of issue of such shares is prior to the record date for the first
Quarterly Dividend Payment Date, in which case dividends on such shares shall
begin to accrue from the date of issue of such shares, or unless the date of
issue is a Quarterly Dividend Payment Date or is a date after the record date
for the determination of

                                      B-2
<PAGE>

holders of shares of Series A Junior Participating Preferred Stock entitled to
receive a quarterly dividend and before such Quarterly Dividend Payment Date, in
either of which events such dividends shall begin to accrue and be cumulative
from such Quarterly Dividend Payment Date. Accrued but unpaid dividends shall
not bear interest. Dividends paid on the shares of Series A Junior Participating
Preferred Stock in amount less than the total amount of such dividends at the
time accrued and payable on such shares shall be allocated pro rata on a
share-by-share basis among all such shares at the time outstanding. The Board of
Directors may fix a record date for the determination of holders of shares of
Series A Junior Participating Preferred Stock entitled to receive payment of a
dividend or distribution declared thereon, which record date shall be not more
than 60 days prior to the date fixed for the payment thereof.

SECTION 3.  VOTING RIGHTS.

      The holders of shares of Series A Junior Participating Preferred Stock
shall have the following voting rights:

      (a) Subject to the provision for adjustment hereinafter set forth, each
share of Series A Junior participating Preferred Stock shall entitle the holder
thereof to 100 votes on all matters submitted to a vote of the stockholders of
the Company. In the event the Company shall at any time declare or pay any
dividend on the Common Stock payable in shares of Common Stock, or effect a
subdivision or combination or consolidation of the outstanding shares of Common
Stock (by reclassification or otherwise than by payment of a dividend in shares
of Common Stock) into a greater or lesser number of shares of Common Stock, then
in each such case the number of votes per share to which holders of shares of
Series A Junior Participating Preferred Stock were entitled immediately prior to
such event shall be adjusted by multiplying such number by a fraction, the
numerator of which is the number of shares of Common Stock outstanding
immediately after such event and the denominator of which is the number of
shares of Common Stock that were outstanding immediately prior to such event.

      (b) Except as otherwise provided herein, in any other resolution creating
a series of preferred stock or any similar stock, in any amendment to the
Certificate of Incorporation of the Company or by law, the holders of shares of
Series A Junior Participating Preferred Stock and the holders of shares of
Common Stock and any other capital stock of the Company having general voting
rights shall vote together as one class on all matters submitted to a vote of
stockholders of the Company.

      (c) Except as set forth herein, or as otherwise provided by law, holders
of Series A Junior Participating Preferred Stock shall have no special voting
rights and their consent shall not be required (except to the extent they are
entitled to vote with holders of Common Stock as set forth herein) for taking
any corporate action.

SECTION 4.  CERTAIN RESTRICTIONS.

      (a) Whenever quarterly dividends or other dividends or distributions
payable on the Series A Junior Participating Preferred Stock as provided in
Section 2 are in arrears, thereafter and until all accrued and unpaid dividends
and distributions, whether or not declared, on shares

                                      B-3
<PAGE>

of Series A Junior Participating Preferred Stock outstanding shall have been
paid in full, the Company shall not:

            (i) declare or pay dividends, or make any other distributions, on
any shares of stock ranking junior (either as to dividends or upon liquidation,
dissolution or winding up) to the Series A Junior Participating Preferred Stock;

            (ii) declare or pay dividends, or make any other distributions, on
any shares of stock ranking on a parity (either as to dividends or upon
liquidation, dissolution or winding up) with the Series A Junior Participating
Preferred Stock, except dividends paid ratably on the Series A Junior
Participating Preferred Stock and all such parity stock on which dividends are
payable or in arrears in proportion to the total amounts to which the holders of
all such shares are then entitled;

            (iii) redeem or purchase or otherwise acquire for consideration
shares of any stock ranking junior (either as to dividends or upon liquidation,
dissolution or winding up) to the Series A Junior Participating Preferred Stock,
provided that the Company may at any time redeem, purchase or otherwise acquire
shares of any such stock in exchange for shares of any stock of the Company
ranking junior (either as to dividends or upon dissolution, liquidation or
winding up) to the Series A Junior Participating Preferred Stock; or

            (iv) redeem or purchase or otherwise acquire for consideration any
shares of Series A Junior Participating Preferred Stock, or any shares of stock
ranking on a parity with the Series A Junior Participating Preferred Stock,
except in accordance with a purchase offer made in writing or by publication (as
determined by the Board of Directors) to all holders of such shares upon such
terms as the Board of Directors, after consideration of the respective annual
dividend rates and other relative rights and preferences of the respective
series and classes, shall determine in good faith will result in fair and
equitable treatment among the respective series or classes.

      (b) The Company shall not permit any subsidiary of the Company to purchase
or otherwise acquire for consideration any shares of stock of the Company unless
the Company could, under paragraph (a) of this Section 4, purchase or otherwise
acquire such shares at such time and in such manner.

SECTION 5.  REACQUIRED SHARES.

      Any shares of Series A Junior Participating Preferred Stock purchased or
otherwise acquired by the Company in any manner whatsoever shall be retired and
cancelled promptly after the acquisition thereof. All such shares shall upon
their cancellation become authorized but unissued shares of preferred stock and
may be reissued as part of a new series of preferred stock subject to the
conditions and restrictions on issuance set forth herein, in a resolution of the
Board of Directors, in the Certificate of Incorporation of the Company, or in
any other Certificate of Amendment creating a series of preferred stock or any
similar stock or as otherwise required by law.

                                      B-4
<PAGE>

SECTION 6.  LIQUIDATION DISSOLUTION OR WINDING UP.

      Upon any liquidation, dissolution or winding up of the Company, no
distribution shall be made (a) to the holders of shares of stock ranking junior
(either as to dividends or upon liquidation, dissolution or winding up) to the
Series A Junior Participating Preferred Stock unless, prior thereto, the holders
of shares of Series A Junior Participating Preferred Stock shall have received
the greater of (i) $100 per share, plus an amount equal to accrued and unpaid
dividends and distributions thereon, whether or not declared, to the date of
such payment, or (ii) an aggregate amount per share, subject to the provision
for adjustment hereinafter set forth, equal to 100 times the aggregate amount to
be distributed per share to holders of shares of Common Stock, or (b) to the
holders of shares of stock ranking on a parity (either as to dividends or upon
liquidation, dissolution or winding up) with the Series A Junior Participating
Preferred Stock, except distributions made ratably on the Series A Junior
Participating Preferred Stock and all such parity stock in proportion to the
total amounts to which the holders of all such shares are entitled upon such
liquidation, dissolution or winding up. In the event the Company shall at any
time declare or pay any dividend on the Common Stock payable in shares of Common
Stock, or effect a subdivision or combination or consolidation of the
outstanding shares of Common Stock (by reclassification or otherwise than by
payment of a dividend in shares of Common Stock) into a greater or lesser number
of shares of Common Stock, then in each such case the aggregate amount to which
holders of shares of Series A Junior Participating Preferred Stock were entitled
immediately prior to such event under the proviso in clause (a) of the preceding
sentence shall be adjusted by multiplying such amount by a fraction, the
numerator of which is the number of shares of Common Stock outstanding
immediately after such event and the denominator of which is the number of
shares of Common Stock that were outstanding immediately prior to such event.

SECTION 7.  CONSOLIDATION, MERGER, ETC.

      In case the Company shall enter into any consolidation, merger,
combination or other transaction in which the shares of Common Stock are
exchanged for or changed into other stock or securities, cash and/or any other
property, then in any such case each share of Series A Junior Participating
Preferred Stock shall at the same time be similarly exchanged or changed into an
amount per share, subject to the provision for adjustment hereinafter set forth,
equal to 100 times the aggregate amount of stock, securities, cash and/or any
other property payable in kind), as the case may be, into which or for which
each share of Common Stock is changed or exchanged. In the event the Company
shall at any time declare or pay any dividend on the Common Stock payable in
shares of Common Stock, or effect a subdivision or combination or consolidation
of the outstanding shares of Common Stock (by reclassification or otherwise than
by payment of a dividend in shares of Common Stock) into a greater or lesser
number of shares of Common Stock, then in each such case the amount set forth in
the preceding sentence with respect to the exchange or change of shares of
Series A Junior Participating Preferred Stock shall be adjusted by multiplying
such amount by a fraction, the numerator of which is the number of shares of
Common Stock outstanding immediately after such event and the denominator of
which is the number of shares of Common Stock that were outstanding immediately
prior to such event.

                                      B-5
<PAGE>

SECTION 8.  NO REDEMPTION.

      The shares of Series A Junior Participating Preferred Stock shall not be
redeemable, except as otherwise provided herein.

SECTION 9.  RANK.

      The Series A Junior Participating Preferred Stock shall rank, with respect
to the payment of dividends and the distribution of assets, junior to all series
of any other class of the Company's preferred stock.

SECTION 10.  AMENDMENT.

      The Certificate of Incorporation of the Company shall not be amended in
any manner, nor shall the Board of Directors take any action, which would
materially alter or change the powers, preferences or special rights of the
Series A Junior Participating Preferred Stock so as to affect them adversely
without the affirmative vote of the holders of at least two-thirds of the
outstanding shares of Series A Junior Participating Preferred Stock, voting
together as a single class.

SECTION 11.  FRACTIONAL SHARES.

      Series A Junior Participating Preferred Stock may be issued in fractions
of a share, which shall entitle the holder, in proportion to such holder's
fractional shares, to exercise voting rights, receive dividends, participate in
distributions and to have the benefit of all other rights of holders of Series A
Junior Participating Preferred Stock.

      IN WITNESS WHEREOF,  First Federal Financial Bancorp,  Inc. has caused
this  certificate  to be  executed  by  its  Chairman  and  attested  by its
Secretary this 21st day of May, 2001.

                                     FIRST FEDERAL FINANCIAL BANCORP,
                                          INC.

Attest:

By: ______________________           By:  ______________________
    Edith M. Daniels                      Thomas D. Phillips
    Secretary                             Chairman

                                      B-6
<PAGE>

                                                                       EXHIBIT C

               [FIRST FEDERAL FINANCIAL BANCORP, INC. LETTERHEAD]

                                  May __, 2001

Dear Stockholders:

      On May 21, 2001, the Board of Directors adopted a Stockholder Protection
Rights Agreement. This letter briefly describes the Rights Agreement and the
Board's reasons for adopting it.

      The Rights Agreement was not adopted so as to preclude any specific effort
to acquire control of the Company. Rather, it was adopted to protect
stockholders against attempts to acquire control of the Company by means of
"creeping" accumulation of shares in the open market, a two-tier tender offer,
an offer at less than a full and fair price or other prevalent takeover tactics
which the Board believes are not in your best interests.

      More than 1,900 U.S. corporations and financial institutions have
considered it prudent, in light of the current takeover environment, to adopt
stockholder protection plans similar to the Rights Agreement.

      The Rights Agreement is not intended to and will prevent a takeover of the
Company at a full and fair price. However, it may cause substantial dilution to
a person or group that beneficially acquires 10% or ore of the Company's Common
Stock (except for offers to acquire all of the Company's Common Stock at a price
and on terms determined by at least a majority of the Board of Directors to be
both adequate and otherwise in the best interests of the Company and its
stockholders) unless the Rights are first redeemed by the Board of Directors.

      The Rights Agreement does not in any way weaken the Company's financial
strength or interfere with its business plans. The issuance of the Rights has no
dilutive effect, will not affect reported earnings per share, is not currently
taxable to the Company or you and will not change the way in which the Company's
shares are traded.

      The Rights should not interfere with any merger or other business
combination that is in the best interests of the Company and its stockholders,
since the Board has the ability to approve any such transaction and since the
Rights generally may be redeemed by the Company at $0.01 per Right in cash prior
to the tenth day (or such earlier or later date as the Board may decide) after
it is announced that a person or group has acquired beneficial ownership of 10%
or more of the Company's Common Stock.

      A summary of the terms of the Rights Agreement is enclosed. The summary is
not complete and is qualified in its entirety by the Rights Agreement, a copy of
which can be obtained free of charge from the Company, 415 Center Street,
Ironton, Ohio 45638, Attention: Edith M. Daniels, Secretary.

                                      C-1
<PAGE>

      In adopting the Rights Agreement, the Board has expressed its confidence
in the Company's future and the Board's determination that you, the
stockholders, be given every opportunity to participate fully in that future.

                               On behalf of the Board of Directors,

                               Thomas D. Phillips
                               Chairman

                                      C-2<PAGE>

Exhibit 4.9       Agreement, dated March 23, 2001, between Gemini Genomics UK
                  Limited and CuraGen Corporation

<PAGE>

                               DATED 23 MARCH 2001

                           GEMINI GENOMICS UK LIMITED

                                       AND

                               CURAGEN CORPORATION

                        ---------------------------------
                                    AGREEMENT

                        RELATING TO PROVISION OF SAMPLES
                        ---------------------------------

                                 ARNOLD & PORTER
                                    TOWER 42
                               25 OLD BROAD STREET
                                 LONDON EC2N 1HO

            Confidential Treatment Requested and the Redacted Material
                has been separately filed with the Commission.
<PAGE>

                                TABLE OF CONTENTS

<TABLE>
<CAPTION>

                                                                     Page No.
                                                                     --------
<S>                                                                  <C>
1.   DEFINITIONS AND INTERPRETATION........................................3

2.   PROVISION OF DNA SAMPLES..............................................7

3.   FEES..................................................................7

4.   INTELLECTUAL PROPERTY.................................................7

5.   WARRANTIES, LIABILITY AND INDEMNITY...................................8

6.   CONFIDENTIALITY.......................................................8

7.   MISCELLANEOUS........................................................10

</TABLE>

                                       2
<PAGE>

                                    AGREEMENT

THIS AGREEMENT is made the 23d day of March 2001

BETWEEN:

(1)      GEMINI GENOMICS UK LIMITED whose principal place of business is at 162
         Science Park, Milton Road, Cambridge CB4 OGH ("Gemini"); and

(2)      CURAGEN CORPORATION whose principal place of business is at 555 Long
         Wharf Drive, New Haven, CT, USA ("CuraGen").

WHEREAS:

(A)      Gemini has collected a broad range of DNA and clinical data from human
         populations across certain disease areas which can be used to identify
         variations to specific genes and to determine the clinical relevance of
         genes with unknown function.

(B)      CuraGen wishes to obtain certain DNA samples and associated clinical
         data from Gemini and Gemini has agreed to provide such samples on the
         terms set out herein.

WHO HAVE AGREED AS FOLLOWS:

DEFINITIONS AND INTERPRETATION

1.       DEFINITIONS AND INTERPRETATION

         1.1     In this Agreement and in the Schedules to this Agreement the
                 following words and phrases shall have the following meanings
                 unless the context requires otherwise.

                 1.1.1     "AFFILIATE" - any company, partnership or other
                           entity which directly or indirectly Controls, is
                           Controlled by or is under common Control with, either
                           Party including as a Subsidiary or Holding Company;

                 1.1.2     "AGREEMENT" - this agreement and any and all
                           schedules, appendices and other addenda to it as may
                           be varied from time to time in accordance with the
                           provisions of this Agreement;

                 1.1.3     "[***] SAMPLES" - the DNA Samples derived from [***]
                           twins with a [***] as set out in Schedule 1;

                 1.1.4     "BUSINESS DAY" - 9.30 am to 5.30 pm on a day other
                           than a Saturday, Sunday, bank or other public holiday
                           in England and Wales or the USA;

                 1.1.5     "CLINICAL DATA" - the phenotypic data in Gemini's
                           possession and control in each case relating to the
                           [***] Samples or the [***] Samples and provided by
                           Gemini to CuraGen pursuant to Clause 2

                                       3
<PAGE>

                           including, without limitation, the data described on
                           Schedules I and 2 attached hereto;

                 1.1.6     "COMPETENT AUTHORITY" - any local or national agency,
                           authority, department, inspectorate, minister,
                           ministry official or public or statutory person
                           (whether autonomous or not) of or of any government
                           of any country having jurisdiction over the Agreement
                           or any of the Parties or over the development or
                           marketing of medicinal products including the
                           European Commission, The Court of first instance and
                           the European Court of Justice;

                 1.1.7     "CONFIDENTIAL INFORMATION" - any trade secrets, Know
                           How, intellectual property rights or confidential
                           information relating to the business affairs or
                           finances of one of the other Parties supplied or
                           otherwise made available or coming into their
                           possession in relation to this Agreement (it being
                           understood that the Sample Results shall be
                           Confidential Information of CuraGen for purposes of
                           this Agreement);

                 1.1.8     "CONTROL" - means the ownership of more than 50% of
                           the issued share capital or the legal power to direct
                           or cause the direction of the general management and
                           policies of the Party in question;

                 1.1.9     "DNA SAMPLES" - those clinical samples of human DNA
                           in Gemini's possession and control which are provided
                           by Gemini pursuant to Clause 2;

                 1.1.10    "DOCUMENTS" - paper, notebooks, books, files,
                           ledgers, records, tapes, discs, diskettes, CDROM and
                           any other media on which Know How can be permanently
                           stored or recorded;

                 1.1.11    "FORCE MAJEURE" - in relation to any Party any event
                           or circumstance which is beyond the reasonable
                           control of that Party which event that Party could
                           not reasonably be expected to have taken into account
                           at the date of this Agreement and which results in or
                           causes the failure of that Party to perform any or
                           all of its obligations under this Agreement including
                           act of God, lightning, fire, storm, flood,
                           earthquake, accumulation of snow or ice, lack of
                           water arising from weather or environmental problems,
                           strike, lockout or other industrial disturbance, act
                           of the public enemy, war declared or undeclared,
                           threat of war, terrorist act, blockade, revolution,
                           riot insurrection, civil commotion , public
                           demonstration, sabotage, act of vandalism prevention
                           from or hindrance in obtaining in any materials,
                           energy or other supplies, explosion, fault or failure
                           of plant or machinery (which could not have been
                           prevented by Good Industry Practice), governmental
                           restraint, act of legislature and directive or
                           requirement of a Competent Authority governing either
                           Party provided that lack of

                                       4
<PAGE>

                           funds shall not be interpreted as a cause beyond the
                           reasonable control of that Party;

                 1.1.12    "KNOW HOW" -  unpatented technical and other
                           information which is not in the public domain
                           including, ideas, concepts, inventions, discoveries,
                           data, formulae, specifications, information relating
                           to material, procedures for experiments and tests and
                           results of experimentation and testing, results or
                           research development including laboratory records,
                           clinical trial data, case report forins, data
                           analyses, reports or summaries and information
                           contained in submissions to and information from
                           ethical committees and Competent Authorities;

                 1.1.13    "MATERIAL" - Documents and any chemical or biological
                           substances including any:-

                           (a) organic or inorganic element or compound;

                           (b) nucleotide or nucleotide sequence including DNA
                               and RNA sequence;

                           (c) gene;

                           (d) vector or construct including plasmids, phages or
                               viruses;

                           (e) host organism including bacteria, fungi, algae,
                               protozoa and hybridomas;

                           (f) eukaryotic or prokaryotic cell line or expression
                               system or any development strain or product of
                               that cell line or expression system;

                           (g) protein including any peptide or amino acid
                               sequence, enzyme, antibody or protein conferring
                               target properties and any fragment of a protein
                               or a peptide enzyme or antibody;

                           (h) drug or pro-drug;

                           (i) assay or reagent; or any other genetic or
                               biologic material or micro-organism;
                               multi-cellular plants;

                           (j) data for the derivation of molecular structures
                               including NMR spectra, X Ray diffraction
                               patterns, and other primary experimental
                               information, assignments and other calculations,
                               required for determination of the structure, and
                               co-ordinates of the derived molecular structure;

                           (k) computer programmes or algorithms.

                 1.1.14    "[***] SAMPLES" - the DNA Samples derived from [***]
                           case and control subjects;

                                       5
<PAGE>

                 1.1.15    "PARTIES" - Gemini and CuraGen and "PARTY" means
                           either of them;

                 1.1.16    "PATENT RIGHTS" - patent applications or patents,
                           author certificates, inventor certificates, utility
                           certificates, improvement patents and models and
                           certificates of addition and all foreign counterparts
                           of them and includes any divisions, renewals,
                           continuations, continuations-in-part, extensions,
                           reissues, substitutions, confirmations,
                           registrations, revalidation or additions of or to
                           them, as well as any supplementary protection
                           certificate in respect of them;

                 1.1.17    "SAMPLE RESULTS" - any and all results (including,
                           without limitation, all Patent Rights, Know-How and
                           Material) which are created, conceived or reduced to
                           practice by CuraGen during the term of this
                           Agreement through its use of the Samples and/or the
                           Clinical Data;

                 1.1.18    "SAMPLES" - the [***] of each of the [***] Samples
                           and the [***] Samples;

                 1.1.19    "SUBSIDIARY OR HOLDING COMPANY" - shall have the
                           meaning ascribed to those expressions by Section 736
                           of the Companies Act 1985 (as amended);

1.2              In this Agreement:-

                 1.2.1     unless the context otherwise requires all references
                           to a particular Clause, paragraph or Schedule shall
                           be a reference to that Clause, paragraph or Schedule,
                           in or to this Agreement as it may be amended from
                           time to time pursuant to this Agreement;

                 1.2.2     the table of contents and headings are inserted for
                           convenience only and shall be ignored in construing
                           this Agreement;

                 1.2.3     unless the contrary intention appears words importing
                           the masculine gender shall include the feminine and
                           vice versa and words in the singular include the
                           plural and vice versa;

                 1.2.4     unless the contrary intention appears words denoting
                           persons shall include any individual, partnership,
                           company, corporation, joint venture, trust,
                           association, organisational or other entity, in each
                           case whether or not having separate legal
                           personality;

                 1.2.5     reference to the words "include" or "including" are
                           to be construed without limitation to the generality
                           of the preceding words; and

                 1.2.6     reference to any statute or regulation includes any
                           modification or re-enactment of that statute or
                           regulation.

                                       6
<PAGE>

2.       PROVISION OF DNA SAMPLES

         2.1    By [***] Gemini shall provide CuraGen with the Samples and
                associated Clinical Data relating to the Samples.

         2.2    CuraGen shall use the Samples for determining the clinical
                relevance of genes only and shall not use the Samples for the
                production or sale of any products or for any clinical use or
                any use in humans. For the avoidance of doubt, CuraGen may use
                the Sample Results without restriction.

         2.3    The provision of the Samples and associated Clinical Data by
                Gemini to CuraGen pursuant to this Agreement shall be subject to
                any applicable legal and/or regulatory requirements.

         2.4    The Samples and associated Clinical Data shall be kept in a
                secure environment at CuraGen's premises. CuraGen shall use
                commercially reasonable efforts to protect the Samples and
                associated Clinical Data against theft, damage, loss, misuse
                and/or unauthorised access.

         2.5    CuraGen will not permit the Samples or associated Clinical Data
                to come into the possession or control of any person other than
                employees, agents, directors, consultants or professional
                advisors of CuraGen who are bound in writing to obligations
                comparable to those set forth in Clause 6.

         2.6    In handling the Samples, CuraGen shall comply with all local
                laws and requirements.

         2.7    The Samples are provided by Gemini to CuraGen on a non-exclusive
                basis and Gemini shall be free to use and to supply to third
                parties such quantities of any samples (including samples from
                the same set of individuals from whom the Samples are derived)
                as Gemini may in its sole discretion decide.

3.       FEES

         3.1    In consideration of the provision of the Samples pursuant to
                Clause 2, CuraGen shall pay to Gemini a fee of US [***] per
                Sample. CuraGen shall pay the fees per sample within fourteen
                (14) days of receipt of the Samples and associated Clinical Data
                supported by an appropriately detailed invoice from Gemini

         3.2    Payments to Gemini under this Agreement shall be made by
                electronic transfer to such bank account of Gemini as Gemini may
                notify to CuraGen.

4.       INTELLECTUAL PROPERTY

         4.1    Any and all Sample Results generated by CuraGen shall vest in
                and be owned by CuraGen.

                                       7
<PAGE>

         4.2    Gemini shall at the request of the CuraGen execute all documents
                and do all other acts and things as may be reasonably required
                in order to vest fully and effectively all rights in and to the
                Sample Results in CuraGen.

         4.3    Except as expressly set out herein no rights or licenses are
                granted by either Party hereunder.

5.       WARRANTIES, LIABILITY AND INDEMNITY

         5.1    Each Party represents and warrants to the other Party that:

                5.1.1  it has legal power, authority and right to enter into
                       this Agreement and to perform its respective obligations
                       in this Agreement; and

                5.1.2  it is not at the date of this Agreement a party to any
                       agreement, arrangement or understanding with any third
                       party which in any significant way prevents it from
                       fulfilling any of its material obligations under the
                       terms of this Agreement.

                5.1.3  Gemini hereby represents and warrants to CuraGen:

                       5.1.3.1     that the Clinical Data contains the
                                   information on Schedule I or 2 for each
                                   patient providing DNA Samples and

                       5.1.3.2.    that it has obtained, and will continue to
                                   obtain, informed consent from all patients
                                   and human subject volunteers that provide
                                   Clinical Data and materials and/or samples
                                   comprising the DNA Samples.

         5.2    Except as is expressly stated herein no other representation,
                warranty is made or given by or on behalf of either Party. In
                particular, and without limitation, Gemini gives no warranty of
                merchantability or fitness for particular purpose or any
                guarantee or warranty of any kind express or implied in relation
                to the [***] Samples, the [***] Samples or the associated
                Clinical Data.

         5.3    Neither Party shall be liable to the other in contract, tort,
                negligence, breach of statutory duty or otherwise for any
                economic loss or other loss of turnover, profits, business or
                goodwill or any loss, damage, costs or expenses of any nature
                whatsoever incurred or suffered by the other or its Affiliates
                of an indirect or consequential nature arising out of or in
                connection with this Agreement.

6.       CONFIDENTIALITY

         6.1    Each of the Parties undertakes and agrees to:

                                       8
<PAGE>

                6.1.1  use the Confidential Information only for the purposes
                       envisaged under this Agreement and not to use the same
                       for any other purpose whatsoever;

                6.1.2  ensure that only those of its officers and employees who
                       are directly concerned with the carrying out of this
                       Agreement have access to the Confidential Information on
                       a strictly applied "need to know" basis and are informed
                       of the secret and confidential nature of it;

                6.1.3  keep the Confidential Information secret and confidential
                       and not directly or indirectly to disclose or permit to
                       be disclosed, make available or pen-nit to be made
                       available the same to any third party (save as provided
                       in Clause 6.3.5) for any reason without the prior written
                       consent of the disclosing Party;

                6.1.4  keep the Confidential Information separate at all times
                       from all other Know How which it may hold;

                6.1.5  clearly identify the Confidential Information as
                       confidential.

         6.2    Each Party agrees not to disclose any of the terms of this
                Agreement or its existence to any third party without the prior
                written consent of the other Party.

         6.3    The obligations of confidence referred to in Clause 6.1 shall
                not extend to any Confidential Information which:-

                6.3.1  is or becomes generally available to the public otherwise
                       than by reason of breach by a recipient Party of the
                       provisions of this Clause;

                6.3.2  is known to the recipient Party and is at its free
                       disposal (having been generated independently by the
                       recipient Party or a third party in circumstances where
                       it has not been derived directly or indirectly from the
                       disclosing Party's Confidential Information)prior to its
                       receipt from the disclosing Party provided that evidence
                       of such knowledge is furnished by the recipient Party to
                       the disclosing Party within 28 days of receipt of that
                       Confidential Information;

                6.3.3  is subsequently disclosed to the recipient Party without
                       obligations of confidence by a third party owing no such
                       obligations to the disclosing Party in respect of that
                       Confidential Information;

                6.3.4  is required by law to be disclosed (including as part of
                       any regulatory submission or approval process) and then
                       only when prompt written notice of this requirement has
                       been given to the disclosing Party so that it may, if so
                       advised, seek appropriate relief to prevent such
                       disclosure provided always that in such circumstances
                       such disclosure shall be only to the extent so required
                       and shall be subject to prior consultation with the
                       disclosing Party with a view to agreeing timing and
                       content of such disclosure; or

                                       9
<PAGE>

                6.3.5  is disclosed to any Affiliate or the employees,
                       directors, agents, consultants and professional advisors
                       of the recipient Party, provided that such persons are
                       bound in writing to the obligations of confidentiality
                       set forth in this Clause 6;.

         6.4    All Confidential Information disclosed by the disclosing Party
                to the recipient Party shall remain the property of the
                disclosing Party. In the event that a court or Competent
                Authority assumes partial or complete control over the assets of
                a recipient Party based on the Insolvency Event of that Party,
                the recipient Party shall:

                6.4.1  promptly notify such court or Competent Authority:

                       (a)   that Confidential Information received from the
                             disclosing Party under this Agreement remains the
                             property of the Disclosing Party; and

                       (b)   of the confidentiality obligations under this
                             Agreement; and

                6.4.2  to the extent permitted by law, take all steps necessary
                       or desirable to maintain the confidentiality and security
                       of the disclosing Party's Confidential Information and to
                       ensure that the court or Competent Authority maintains
                       that Confidential Information in confidence in accordance
                       with this Agreement.

         6.5    The obligations of the Parties under Clause 6.1 to 6.4 shall
                survive for a period of five (5) years from the date of this
                Agreement.

7.       MISCELLANEOUS

         7.1    Neither Party shall without the prior written consent of the
                other, such consent not to be unreasonably withheld, assign the
                benefit and/or burden of this Agreement to any third party other
                than an Affiliate.

         7.2    If a Party is unable to perform any of its obligations under
                this Agreement due to an event of Force Majeure, such Party
                shall be excused such performance (but only such performance)
                during the period of such Force Majeure event.

         7.3    The validity, construction and interpretation of this Agreement
                and any determination of the performance which it requires shall
                be governed by English law. All disputes between the Parties
                arising out of the circumstances and relationships contemplated
                by this Agreement including disputes relating to the validity,
                construction or interpretation of this Agreement, and including
                disputes relating to pre-contractual representations which
                result in any action or proceedings, shall be subject to the
                exclusive jurisdiction of the English Courts.

         7.4    Except as expressly provided in this Agreement nothing herein
                deprives either Party or constitutes a waiver by either Party of
                any of its rights or remedies under common law, statute or
                otherwise.

                                       10
<PAGE>

         7.5    This Agreement constitutes the entire agreement and
                understanding between the Parties and supersedes all prior oral
                or written understandings, arrangements, representations or
                agreements between them relating to the subject matter of this
                Agreement provided that this does not remove any right of action
                by either Party in respect of any fraudulent misrepresentation,
                fraudulent concealment or other fraudulent action.

         7.6    All formal notices to be given pursuant to this agreement shall
                be in writing and shall be delivered by hand, post or facsimile
                to the address of the Parties set out above (or such other
                address as may be notified by a Party to the other from time to
                time in accordance with this Clause) and in the case of a
                facsimile with a confirmation copy being sent by post. Notices
                shall be deemed to have been received:

                7.6.1    if delivered by courier, at the time of delivery;

                7.6.2    if sent by post:

                         (a)   where posted in the country of the addressee,
                               on the second  working day following the day of
                               posting; and

                         (b)   where posted in any other country, on the fifth
                               working day following the day of posting;

                7.6.3    if sent by facsimile, on acknowledgement by the
                         recipient facsimile receiving equipment on a Business
                         Day if the acknowledgement occurs before 1700 hours
                         local time on a Business Day of the recipient and in
                         any other case on the following Business Day.

         7.7    The activities of the Parties contemplated pursuant to this
                Agreement shall not constitute a partnership and neither Party
                is the agent of the other Party or has the authority to bind the
                other Party in any way except as provided in this Agreement.

         7.8    Each Party shall bear its own legal costs and other expenses
                incurred in the negotiation, preparation, execution and
                implementation of this Agreement.

         7.9    Any press releases to be made by either Party relating to this
                Agreement will require the approval of the other Party.

         7.10   This Agreement may be executed in any number of counterparts and
                by the Parties by separate counterparts, each of which when so
                executed shall be an original and all of which shall constitute
                one and the same instrument.

         7.11   The operation of the Contract (Rights of Third Parties) Act 1999
                is hereby expressly excluded save that the Parties acknowledge
                and agree that Affiliates of either Party may enforce against
                the Parties (and a person who is the lawful successor to or a
                permitted assignee of the rights of a Party) the rights and
                benefits under this Agreement in accordance with that Act.

                                       11
<PAGE>

IN WITNESS WHEREOF the Parties have executed this document the day and year
first above written.

SIGNED by
for and on behalf of
GEMINI GENOMICS UK LIMITED
in the presence of:

SIGNED by
for and on behalf of
CURAGEN CORPORATION
in the presence of:

                                       12
<PAGE>

                                   SCHEDULE 1

                        [***] SAMPLES AND PHENOTYPIC DATA

                                       13
<PAGE>

                                   SCHEDULE 2

                        [***] SAMPLES AND PHENOTYPIC DATA

                                       14

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00026-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00026-of-00352.parquet"}]]